


Kashyap Tele-Medicines Limited



26th **ANNUAL
REPORT**
2019-2020

CORPORATE INFORMATION

BOARD OF DIRECTORS:

Mr. Amit Agrawal	(DIN: 00169061)	Managing Director
Mr. Dinesh Jain*	(DIN:00216803)	Non Executive Non Independent Director
Mr. Raghav Agrawal#	(DIN:02264149)	Non Executive Non Independent Director
Ms. Amrita Khetan	(DIN:02781781)	Non Executive Non Independent Director
Mr. Girwarsingh Shekhawat*	(DIN:06940371)	Independent Director
Mr. Mayank Khetan#	(DIN:02412971)	Independent Director
Ms. Surabhi Agrawal	(DIN:06940379)	Independent Director
Mr. Devkinandan Sharma	(DIN:07900496)	Independent Director

*Resigned w.e.f. 21st May, 2019

#Appointed w.e.f. 21st May, 2019

COMPANY SECRETARY & COMPLIANCE OFFICER:

CS Perna Kakkar

CHIEF FINANCIAL OFFICER :

Mr. Dinesh Jain (Upto 13th November, 2019)

Mr. Raghav Agrawal (w.e.f. 14th November, 2019)

STATUTORY AUDITORS:

M/s. Saremal & Co.

Practicing Chartered Accountants
Ahmedabad

INTERNAL AUDITORS:

M/s. Jagdish Verma & Co.

Practicing Chartered Accountants
Ahmedabad

SECRETARIAL AUDITORS:

M/s. SPANJ & Associates

Practicing Company Secretaries
Ahmedabad

BANKERS:

HDFC Bank Limited
Bank of India

LISTED AT:

BSE Limited

SCRIP CODE:

531960

REGISTERED OFFICE :

Kashyap Tele-Medicines Limited
CIN : L29110MH1995PLC085738
2nd Floor, Pushpawati Building No. 2
Chandanwadi, Girgaon Road,
Mumbai – 400 002

E-mail ID:- investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

CORPORATE OFFICE:

UL/8, Upper Floor, "Suryarath", 1st Floor, Panchwati,
1st Lane, Ambawadi,
Ahmedabad – 380 006
Phone No.: +91 - 6359637788

E-mail ID:- investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

REGISTRAR AND SHARE TRANSFER AGENT (RTA):

Link Intime India Private Limited

Corp. Off. : 5th floor, 506 to 508 Amarnath Business Centre - I
(ABC - I), Beside Gala Business Centre,
Nr. St. Xavier's College Corner, Off C G Road,
Ellisbridge, Ahmedabad, Gujarat, 380006

E-mail ID: ahmedabad@linkintime.co.in

CONTENTS

03-35

**Statutory
Reports**



- 3** Notice of AGM
- 10** Directors' Report and Annexures
 - Annexure-A Extract of Annual Return
 - Annexure-B Particulars of Employees
 - Annexure-C Secretarial Audit Report
 - Annexure-D Management Discussion and Analysis Report
 - Annexure-E Form No. AOC-2
- 35** MD and CFO Certification

36-58

**Financial
Statements**



- 36** Independent Auditor's Report
- 40** Balance Sheet
- 41** Statement of Profit and Loss
- 42** Cash Flow Statement
- 44** Notes forming Part of Financial Statements

"Earlier the MCA has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the Companies to share documents with its shareholders through an electronic mode, but further due to ongoing COVID-2019 pandemic the MCA and SEBI vide their various circulars has mandatorily prescribed for sending Notice of the AGM along with the Annual Report through electronic mode only to the Members of the Company and accordingly to comply with the same the Annual Report 2019-2020 will be sent thorough electronic mode (via e-mail) only by the Company. Members are requested to register/update their respective email IDs for receiving further electronic communications."

NOTICE OF 26TH ANNUAL GENERAL MEETING

Notice is hereby given that the 26th Annual General Meeting of the Members of **KASHYAP TELE-MEDICINES LIMITED** will be held on **Friday, 11th day of September, 2020 at 3.00 p.m. IST** through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"), to transact the businesses mentioned below.

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended on 31st March, 2020 including Balance Sheet as at 31st March, 2020, the Statement of Profit and Loss and Cash Flow Statement for the year ended on that date and Report of the Board of Directors and Statutory Auditors thereon.
2. To appoint a Director in place of **Mr. Raghav Agarwal** (DIN: 02264149) Non Executive Non Independent Director, who retires by rotation and being eligible, offer himself for re-appointment.

**On behalf of Board of Directors
For, Kashyap Tele-Medicines Limited**

**Sd/-
Amit Agrawal
Managing Director
DIN: 00169061**

Date: 7th August, 2020

Place: Ahmedabad

Registered Office:

2nd Floor, Pushpawati Building No. 2,
Chandanwadi, Girgaon Road,
Mumbai-400 002, Maharashtra

CIN: L29110MH1995PLC085738

E-mail ID : investor.relations@kashyaptele-medicines.com

NOTES:

1. In view of the ongoing COVID-19 pandemic, restrictions imposed on the movement of people and social distancing norms to be followed, the Ministry of Corporate Affairs ("MCA") vide its Circular No. 20/2020 dated 5th May, 2020 read with Circular No. 14/2020 dated 8th April, 2020 and Circular No. 17/2020 dated 13th April, 2020 (collectively referred to as "MCA Circulars") and SEBI vide its Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated 12th May, 2020 ("SEBI Circular") has allowed the holding of the Annual General Meeting ("AGM") through Video Conferencing (VC)/Other Audio Visual Means (OAVM), without the physical presence of the Members at a common venue. Accordingly in compliance of the said circulars, the 26th AGM of the Company will be held through VC / OAVM.
2. The Company has appointed Central Depository Services (India) Limited (CDSL), to provide VC/OAVM facility for the AGM and ensuing AGM will be held through VC/OAVM.
3. Pursuant to aforesaid MCA Circulars, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM and since, this AGM is being held through VC/OAVM modes, physical attendance of Members has been dispensed with and thus the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
4. Pursuant to Section 113 of the Companies Act, 2013, Institutional/Corporate members can attend and vote through VC/OAVM by submitting a duly certified copy of the Board Resolution authorizing their representative to attend and vote through e-voting on its behalf. In case of joint holders attending the AGM, only such joint holder who is higher in the order of names will be entitled to vote.
5. In compliance with the aforesaid MCA Circulars and SEBI Circular, the 26th Annual Report along with Notice of the AGM including general guidelines for participation at the 26th AGM through VC/OAVM, procedure for remote e-voting including during the AGM, is being sent only by electronic mode to those Members whose E-mail IDs are registered with the Company/Depository/R&T Agent. The same has also been uploaded on the website of the Company, i.e. www.kashyaptele-medicines.com.
6. Members attending the meeting through VC/OAVM, who have not cast their vote by means of remote e-voting, shall be able to exercise their right to vote through e-voting at the AGM. The Members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM through VC/OAVM but shall not be entitled to cast their vote again.
7. Members who have not registered their E-mail IDs are requested to register the same in respect of shares held in electronic form with the Depository through their Depository Participant(s) and in respect of shares held in physical form by writing to the Registrar and Share Transfer Agent (RTA)/Company for receiving all communications including annual report and notices, in electronic mode from the Company.
8. There being no special business, Explanatory Statement pursuant to provision of Section 102 of the Companies Act, 2013 is not applicable to the Company.
9. Members holding shares in physical mode and dematerialized mode are requested to notify immediately the change of their address, email ID and bank particulars to the Registrar and Share Transfer Agent/Depository Participant/Company. In case of any queries, complaints/ grievances, the Shareholders are requested to kindly contact to the RTA/Company.
10. With reference to SEBI Circular No. SEBI/HO/MIRSD/DOP1/CIR/P/2018/73 dated 20th April, 2018, Shareholders whose ledger folios have incomplete details with respect to PAN and Bank Account details or where there is any change in the bank account details provided earlier, they are requested to provide such particulars as are mandatorily required to be furnished to the Issuer Company/RTA for recording the same in the respective shareholders records.

Thus, for better compliance and for the purpose of updation of the correct and valid details, all the shareholders are requested to fill in the all the details as required in the said "KYC Updation Form" which forms a part of this Annual Report and send the signed "KYC Updation Form" to the RTA of the Company and a copy of same to the Company.

11. As per SEBI Notification No. SEBI/LAD-NRO/GN/2018/24 dated 8th June, 2018 and further amendment vide Notification No. SEBI/LAD-NRO/GN/2018/49 dated 30th November, 2018, approval of requests for effecting transfer of securities (except in case of transmission or transposition of securities) has been restricted w.e.f. 1st April, 2019 unless the securities are held in the dematerialized form with the depositories. With the said changes which came into effect from 1st April, 2019, Equity Shares of the Company shall be eligible for transfer only in dematerialized form. Therefore, the Members are requested to take necessary actions to dematerialize their physical Equity Shares of the Company promptly. The detailed procedure of conversion of physical shares into dematerialization form is available on the website of Central Depository Services (India) Limited (CDSL), National Securities Depository Limited (NSDL) and Company on their website: www.cdslindia.com, www.nsdl.co.in and www.kashyaptele-medicines.com respectively.
12. Pursuant to the provisions of Section 91 of the Companies Act, 2013 read with Rule 10 of Companies (Management and Administration) Rules, 2014 and pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("hereinafter referred as "Listing Regulations"), as amended from time to time, the Register of Members and Share Transfer Books of the Company will be closed from **Saturday, 5th September, 2020, to Friday, 11th September, 2020** (both days inclusive) for the purpose of the 26th AGM.
13. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013 and all other documents referred to in the notice shall be available for inspection electronically. Members seeking to inspect such documents can send an email to investor.relations@kashyaptele-medicines.com.
14. In case of any queries in regards to information stated in the Annual Report, the Members may write to investor.relations@kashyaptele-medicines.com to receive an email response.
15. In terms of Section 152 of the Companies Act, 2013, Regulations 26(4) and 36(3) of Listing Regulations and Secretarial Standard – 2 issued by the Institute of Company Secretaries of India (ICSI), Information of Director eligible for re-appointment at this AGM are provided in the "Annexure to the Notice".
16. **Process and manner for members opting for voting through Electronic means:**
 - i. In compliance with provisions of Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended

by the Companies (Management and Administration) Amendment Rules, 2015, Regulation 44 of Listing Regulations, Secretarial Standard-2 issued by the ICSI, MCA Circulars and SEBI Circular, the Company is pleased to provide electronic voting facility (remote e-voting during e-voting period and e-voting during the period at which meeting will be conducted) to the Members of the Company so as to facilitate them to cast their vote on all resolution set forth in this notice electronically, through remote e-voting as well as the e-voting service facility provided by CDSL.

- ii. The Members can attend the AGM through the VC/OAVM mode before and after 30 minutes of the scheduled time of the commencement of the Meeting by following the procedure mentioned in part of this Notice. The facility of participation at the AGM through VC/OAVM will be made available to atleast 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
- iii. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
- iv. Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners are maintained by the Depositories as on the **Cut-off date i.e. Friday, 4th September, 2020** shall be entitled to avail the facility of remote e-voting or e-voting at the AGM. Any recipient of the Notice, who has no voting rights as on the Cut-off date, shall treat this Notice as intimation only.
- v. Any person if will become the shareholder of the Company after the dispatch of the Notice of the Annual General Meeting and prior to the **Cut-off date i.e. Friday, 4th September, 2020** shall be entitled to exercise his/her vote electronically i.e. remote e-voting or e-voting by attending the AGM through VC/OAVM.
- vi. Once the vote on a resolution is casted by the shareholder, the shareholder shall not be allowed to change it subsequently.
- vii. Members attending the meeting through VC/OAVM, who have not already cast their vote by means of remote e-voting, shall be able to exercise their right to vote through e-voting at the AGM. The Members who have cast their vote by remote e-voting prior to the AGM may also join the AGM through VC/OAVM but shall not be entitled to cast their vote again.

- viii. The voting rights of the members shall be in proportion to their share in the paid up equity share capital of the Company as on the **Cut-off date i.e. Friday, 4th September, 2020.**
- ix. M/s. SPANJ & Associates, Practicing Company Secretaries, Ahmedabad, has been appointed as the Scrutinizer to scrutinize the remote e-voting process as well as the e-voting on the date of the AGM, in a fair and transparent manner.
- x. The Scrutinizer shall immediately, after the conclusion of voting at AGM, will first count the votes cast at the AGM, thereafter unblock the votes cast through remote e-voting and e-voting in the presence of at least two witnesses not in the employment of the Company. Scrutinizer shall, submit a Scrutiniser's Report of the total votes cast in favour or against, if any, to the Chairman who shall countersign the same and declare the results of the voting forthwith, within 48 hours of conclusion of the AGM.
- xi. The resolutions shall be deemed to be passed on the date of the Meeting, subject to the same being passed with requisite majority.
- **Process for those shareholders whose E-Mail Ids are not registered with the depositories for obtaining login credentials for e-voting for the resolutions proposed in this notice:**
 - I. For Physical shareholders - please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA.
 - II. For Demat shareholders - please provide Demat account details (CDSL-16 digit beneficiary ID or NSDL-16 digit DPID + CLID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by contacting their respective Depository Participant or to Company/RTA.
 - III. The Company/RTA shall coordinate with CDSL and provide the login credentials accordingly.
- **The instructions for shareholders for remote e-voting are as under:**
 - a.) The remote e-voting period shall commence on **Tuesday, 8th September, 2020 at 9.00 a.m. and ends on Thursday, 10th September, 2020 at 5.00 p.m.** During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the **Cut-off date i.e. Friday, 4th September, 2020**, may cast their vote electronically.
 - b.) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting.
 - c.) The shareholders should log on to the e-voting website **www.evotingindia.com**.
 - d.) Click on "Shareholders" module.
 - e.) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
 - OR
 - Alternatively, if you are registered for CDSL's **EASI/EASIEST** e-services, you can log in at **<https://www.cdslindia.com>** from **Login - Myeasi** using your login credentials. Once you successfully log-in to CDSL's **EASI/EASIEST** e-services, click on e-Voting option and proceed directly to cast your vote electronically.
 - f.) Next enter the Image Verification as displayed and Click on Login.
 - g.) If you are holding shares in demat form and had logged on to **www.evotingindia.com** and voted on an earlier e-voting of any company, then your existing password is to be used.

h.) If you are a first time user follow the steps given below:

For Shareholders holding shares in Demat Form and Physical Form	
PAN	<p>Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none"> Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN Field. In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. E.g. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
DOB#	Enter the Date of Birth as recorded in your demat account or in the company records for the said demat account or folio in dd/mm/yyyy format.
Dividend Bank Details*	Enter the Dividend Bank Details as recorded in your demat account or in the company records for the said demat account or folio.

- i.) After entering these details appropriately, click on "SUBMIT" tab.
- j.) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- k.) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- l.) Click on the EVSN of the Company i.e. "Kashyap Tele-Medicines Limited" on which you choose to vote.
- m.) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- n.) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- o.) After selecting the resolution you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- p.) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- q.) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- r.) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- s.) Shareholders can also cast their vote using CDSL's mobile app "m-Voting". The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.

Note for Non – Individual Shareholders and Custodians

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; investor.relations@kashyaptele-medicines.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at www.evotingindia.com. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call 1800225533.

- The instructions for shareholders for e-voting during the AGM are as under:-**

- The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
- Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
- If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.
- Shareholders who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

- The instructions for shareholders attending the AGM through VC/OAVM are as under:**

- Shareholder will be provided with a facility to attend the AGM through VC/OAVM through the CDSL e-Voting system. Shareholders may access the same at <https://www.evotingindia.com> under shareholders'/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVSN of Company will be displayed.
- Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
- Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- For ease of conduct, shareholders who would like to ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast 7 (Seven) days prior to the AGM mentioning their name, demat account number/folio number, email id, mobile number at company mail id i.e. investor.relations@kashyaptele-medicines.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 7 (Seven) days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at company mail id i.e. investor.relations@kashyaptele-medicines.com. These queries will be replied by the Company suitably by email.
- Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM.

Contact Details

Company	:	Kashyap Tele- Medicines Limited CIN: L29110MH1995PLC085738 Regd. Office : 2 nd Floor, Pushpawati Building No. 2, Chandanwadi, Girgaon Road, Mumbai-400002, Maharashtra Corporate Office: UL/8, Upper Floor, Suryarath Complex, Panchwati 1 st Lane Ambawadi, Ahmedabad - 380006 Gujarat E-mail ID: investor.relations@kashyaptele-medicines.com Website: www.kashyaptele-medicines.com Mobile No.: +91-6359637788
Registrar and Transfer Agent	:	Link Intime India Private Limited Corp. Office: 5 th floor, 506 to 508 Amarnath Business Centre - I (ABC - I), Beside Gala Business Centre, Nr. St. Xavier's College Corner, Off C G Road, Ellisbridge, Ahmedabad, Gujarat, 380 006 E-mail ID: ahmedabad@linkintime.co.in Website: www.linkintime.co.in Phone No.: 079-26465179
E-Voting Agency	:	Central Depository Services (India) Limited E-mail ID: helpdesk.evoting@cdslindia.com
Scrutinizer	:	M/s. SPANJ & Associates Practicing Company Secretaries, Ahmedabad E-mail ID: csdoshiac@gmail.com

**On behalf of Board of Directors
For, Kashyap Tele-Medicines Limited**

Date: 7th August, 2020

Place: Ahmedabad

Registered Office:

2nd Floor, Pushpawati Building No. 2,
Chandanwadi, Girgaon Road,
Mumbai-400 002, Maharashtra

CIN: L29110MH1995PLC085738

E-mail ID: investor.relations@kashyaptele-medicines.com

Sd/-

Amit Agrawal

Managing Director

DIN: 00169061

ANNEXURE TO THE NOTICE**DETAILS OF DIRECTOR SEEKING RE-APPOINTMENT AT THE 26TH AGM OF THE COMPANY**

Name	Mr. Raghav Agrawal Non Executive Non Independent Director
DIN	02264149
Date of Birth	20 th April, 1988
Date of First Appointment	21 st May, 2019
Age	32 Years
Educational Qualification	Graduate in Business Administration in Economics from Michigan State University, USA
Experience and expertise	He is having over 10 years experience in expansion of new services, products and strategies. He is an expert in Project Execution, Qualitative and quantitative economic analysis, Strategic Planning, Leadership Development, Customer Engagement and Risk Mitigation.
Remuneration last drawn	NIL
Directorship held in other companies as on 31st March, 2020	<ol style="list-style-type: none"> 1. Amitara Resorts Private Limited 2. Amitara Green Hi-Tech Park Private Limited 3. Amitara Industries Private Limited 4. Artsy Weaves Private Limited 5. Bhagyalakshmi Spintex Private Limited 6. Bienville Estates Enterprise Private Limited 7. Gayatri Weavers Private Limited 8. Jindal Creations Private Limited 9. Jindal Denim (India) Private Limited 10. Jindal Speciality Chemicals India Private Limited 11. Jindal Integrated Textile Park Private Limited 12. Kshipan Estates And Enterprise Private Limited 13. Niharika Threads Private Limited 14. Rosabelle Textiles Private Limited 15. Tarachand Impex Private Limited 16. Uma Weavers Private Limited 17. Yash Weavers Limited
Membership / Chairmanship in Committees of other companies as on 31st March, 2020	YASH WEAVERS LIMITED <ul style="list-style-type: none"> • Audit Committee-Chairman • Nomination and Remuneration Committee-Chairman
Shareholding in the Company as on 31st March, 2020	NIL
Relationship with other Directors / Key Managerial Personnel	Not related to any Director / Key Managerial Personnel
Number of meetings of the Board attended during the Financial Year (2019-2020)	4 out of 5

BOARD OF DIRECTORS' REPORT

To,
The Members,
KASHYAP TELE - MEDICINES LIMITED

Your Directors have pleasure in presenting the 26th Annual Report of the Company together with the Audited Financial Statements and the Auditors' Report thereon for the Financial Year ended, 31st March, 2020.

1. FINANCIAL HIGHLIGHTS:

The summary of the financial results for the year is given below:

(Amount in ₹)

Particulars	31 st March, 2020	31 st March, 2019
Revenue from Operations	20,07,500	19,85,000
Other Income	-	-
Total Revenue	20,07,500	19,85,000
Expenditure:		
Changes in inventories of finished goods, work-in progress and Stock – in Trade	-	-
Employee benefit expense	9,08,384	9,93,320
Depreciation and Amortization Expenses	-	-
Other Expenses	9,52,657	6,82,746
Total Expenses	18,61,041	16,76,066
Profit Before Tax	1,46,459	3,08,934
Tax Expenses:		
Current Tax	33,510	78,162
Tax relating to P.Y.	(20,883)	-
Income tax expenses	12,627	78,162
Profit/ (Loss) for the period	1,33,832	2,30,772
Earning per Equity Share @ of Face Value of ₹ 1/- each (Basic & Diluted)	0.003	0.005

2. HIGHLIGHTS OF PERFORMANCE:

The Total Income of the Company has been increased to ₹ 20,07,500/- in the Financial Year 2019-2020 as compared to ₹ 19,85,000/- in Previous Year 2018-2019 at a increased rate of 1.13%. The total expenses of the Company are ₹ 18,61,041/- in Financial Year 2019-2020 as compared to ₹ 16,76,066/- in Previous Year 2018-2019 at a rate of 11.04%. The Profit of the Company has been decreased to ₹ 1,33,832/- as compared to the Profit of ₹ 2,30,772/- in the Previous Financial Year 2018-2019.

3. IMPACT OF COVID - 19:

The COVID-19 outbreak is an unprecedented global situation that all countries are dealing with the terms of its human and economic consequences and the same has affected majority of people across the globe including of India due to the implementation of lockdown from 24th March 2020 in different phases across the country. Consequently, your company had various impacts of ongoing COVID-19 the same which are briefed as under:

In the first phase of Lockdown, the Company was not in operation as the office premises remained closed. However, in order to continue its operations, the Company has started work from

home facility for its employees which had resulted into starting of its operations on a partial basis. The revenues and profitability of the Company are likely to be impacted and the Company is closely monitoring it and its expected that the business situation would normalize in upcoming period. Further, the Company is taking all the necessary precautions & safety measures for the employees of the Company by way of sanitization of premises, thermal screening of employees, maintaining proper hygiene and social distancing in office.

4. CIRCULATION OF ANNUAL REPORTS IN ELECTRONIC FORM:

In view of the prevailing COVID-19 pandemic situation, the SEBI has dispensed with printing of Annual Reports and further the dispatch of physical copies of Annual Report for Financial Year 2019-2020 to the shareholders has also been exempted by MCA and SEBI.

Accordingly to comply with the above, the Annual Report for the financial year 2019-2020 will be sent through electronic mode (via e-mail) only by the Company as registered with the RTA of the Company. Members are requested to register/ update their respective email IDs for receiving further electronic communications.

A copy of the Annual Report is also available on the Company's website at www.kashyaptele-medicines.com.

5. CHANGE OF E-MAIL ID OF THE COMPANY:

The Company has changed its E-mail ID from "investor.relations@jindalonline.com" to "investor.relations@kashyaptele-medicines.com" w.e.f. 17th July, 2020, due to some technical server issues. Members may please note that any future correspondence with the Company shall be made through the new E-mail ID i.e. "investor.relations@kashyaptele-medicines.com" only, as the old one no more accessible by the Company.

6. CHANGE IN CORPORATE OFFICE OF THE COMPANY:

During the Financial Year under review, the Company has changed its corporate office from "Suryarath", 1st Floor, Panchwati, 1st Lane, Ambawadi, Ahmedabad – 380006" to "UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006", w.e.f. 8th February, 2020 vide approval of Board of Director in their meeting held on 7th February, 2020.

7. DIVIDEND:

Due to inadequate profit the Company is not in any position to recommend any dividend for the Financial Year ended 31st March, 2020.

The Dividend Distribution Policy as per Regulation 43A of the Listing Regulations is not applicable to the Company as it does not fall under top 500 Listed Companies based on its market capitalization as at the end of the Financial Year 31st March, 2020.

8. NON APPLICABILITY OF BUSINESS RESPONSIBILITY REPORT:

The Business Responsibility Report as per Regulation 34(2) of the Listing Regulations is not applicable to the Company as the Company does not fall under top 1000 listed Companies on the basis of market capitalization as at the end of the Financial Year 31st March, 2020.

9. APPLICABILITY OF THE INDIAN ACCOUNTING STANDARDS (IND AS):

Pursuant to the notification dated 16th February, 2015 issued by the Ministry of Corporate Affairs, the Company has adopted the Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 (as amended from time to time) with effect from 1st April, 2017 and the Financial Statement for the Financial Year 2019-2020 are prepared in accordance with Ind AS.

10. SHARE CAPITAL:

a) Authorized Share Capital

There was no change in the Authorised Capital of the Company during the Financial Year 2019-2020. The Authorized Share Capital of the Company as at 31st March, 2020 stood at ₹ 15,00,00,000/-.

b) Issued Share Capital

The Issued Share Capital of the Company as at 31st March, 2020 stood at ₹ 5,00,00,000/-. During the year under review, the Company has not issued shares with differential voting rights nor has granted any stock options or sweat equity. As on 31st March, 2020, none of the Directors of the Company hold any instruments convertible into equity shares of the Company.

c) Subscribed and Paid up Share Capital

The Subscribed and Paid up Share Capital of the Company as at 31st March, 2020 stood at ₹ 4,77,22,000/-.

11. AMOUNTS TRANSFERRED TO RESERVES:

No amount has been transferred to General Reserve.

However the balance of Shares Forfeiture Account of ₹ 11,97,500/- against application money of 2278000 equity shares as forfeited by the Company has been duly transferred to Capital Reserve Account in the Financial Year 2018-2019, in accordance with the applicable accounting provisions.

12. INFORMATION ABOUT SUBSIDIARY/ JOINT VENTURE / ASSOCIATE COMPANY:

The Company does not have any Associate/Subsidiary/Joint Venture Company.

The Company is an Associate Company of M/s. Jindal Worldwide Limited and M/s. Amitara Industries Private Limited having a stake of 31.25% and 25.94%, respectively in your company's equity share capital.

13. EXTRACT OF THE ANNUAL RETURN AS PER SECTION 92(3) OF COMPANIES ACT 2013:

The details forming part of the extract of the Annual Return in Form MGT-9, as required under Section 92 of the Companies Act, 2013, is annexed as **Annexure-A** which forms an integral part of this Report and is also available on the Company's website i.e. <http://www.kashyaptele-medicines.com>.

14. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURE:

Disclosures pertaining to remuneration and other details as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are provided in the prescribed format and is annexed as **Annexure-B** which forms an integral part of this Report.

No employee has received remuneration in excess of the limits set out in rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 during Financial Year 2019-2020.

15. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

Since there was no Dividend declared in past years by the Company, the transfer of unclaimed dividend to Investor Education and Protection Fund is not applicable to the Company.

16. CHANGE IN THE NATURE OF BUSINESS:

There has been no change in the nature of business of the Company during the year. Further, there were no material changes and commitments between the end of the Financial Year of the Company to which the Financial Statements relates and date of Directors' Report affecting the financial position of the Company, except those of COVID-19 as mentioned in financial statements forming part of this Annual Report.

17. MEETINGS OF THE BOARD:

The Board of Directors of the Company met 5 (Five) times during the Financial Year 2019-2020 on 20th May, 2019, 13th July, 2019, 02nd August, 2019, 13th November, 2019 and 7th February, 2020. The maximum gap between two Board Meetings was less than one hundred and twenty days. All material information was circulated/placed to the Directors the meeting, including all such informations required to be made available to the Board as prescribed under Part A of Schedule II of Regulation 17(7) of the Listing Regulations.

Name of Director	Category	Attendance of Meeting of Board of Directors held on				
		20 th May, 2019	13 th July, 2019	02 nd August, 2019	13 th November, 2019	07 th February, 2020
Mr. Amit Agrawal	Managing Director	√	√	√	√	√
Ms. Amrita Khetan	Non Executive Non Independent Director	√	√	√	√	×
*Mr. Raghav Agrawal	Non Executive Non Independent Director	NA	√	√	√	√
Ms. Surabhi Agrawal	Independent Director	√	√	√	√	√
Mr. Devkinandan Sharma	Independent Director	√	×	√	×	√
*Mr. Mayank Khetan	Independent Director	NA	×	√	√	√
Mr. Dinesh Jain	Non Executive Non Independent Director	√	Resigned w.e.f. 21 st May, 2019			
Mr. Girwarsingh Shekhawat	Independent Director	√	Resigned w.e.f. 21 st May, 2019			

* Appointed w.e.f. 21st May, 2019

√ Present

×

18. BOARD OF DIRECTORS:

The Company is well supported by the knowledge and experience of its Directors and Executives. In accordance with the provision of Section 152 of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Raghav Agrawal (DIN: 02264149), Director of the Company will retire by rotation and being eligible, offer himself for re-appointment at the ensuing Annual General Meeting. His brief resume, nature of expertise, details of directorships held in other companies along with his shareholding in the Company; as stipulated under Secretarial Standard 2 and Regulation 36 of the Listing Regulations; is appended as an Annexure to the Notice of this AGM.

Mr. Dinesh Jain (DIN: 00216803), Non-Executive Non Independent Director of the Company, resigned from the Board w.e.f. 21st May, 2019 due to his personal pre-occupations.

Mr. Girwarsingh Shekhawat (DIN: 06940371), Non-Executive Independent Director of the Company, resigned from the Board w.e.f. 21st May, 2019 due to his personal and unavoidable circumstances. Further, he has confirmed that there is no other material reason for his resignation as Director of the Company, other than those cited above.

Your Directors place on record their appreciation for the invaluable contributions and guidance made by Mr. Dinesh Jain and Mr. Girwarsingh Shekhawat during their tenure as Directors of the Company.

At the 25th Annual General Meeting (AGM) held on 21st August, 2019, the shareholders of the Company approved the following:

- Appointment of Mr. Mayank Khetan (DIN:02412971), in the category of Independent Director for a period of 5 years w.e.f 21st May, 2019.
- Appointment of Mr. Raghav Agrawal (DIN:02264149), in the category of Non-Executive Non Independent Director w.e.f 21st May, 2019.
- Re- Appointment of Mrs. Surabhi Agrawal (DIN:06940379), whose first term as an Independent Director of the Company expired on 25th Annual General Meeting and was eligible for re-appointment as an Independent Director for the second term of 5 (five) consecutive years w.e.f. 22nd August, 2019 upto 21st August, 2024.

The Company has received declarations under Section 164 of the Companies Act, 2013 from all the directors of the Company

for the Financial Year 2019-2020, in addition to declaration of compliance under Part C of Schedule V of the Listing Regulations.

19. KEY MANAGERIAL PERSONNEL (KMP):

Pursuant to the provisions of Sections 2(51) and 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (as amended from time to time), the following are the Key Managerial Personnel of the Company:

1. Mr. Amit Agrawal: Managing Director;
2. Mr. Dinesh Jain : Chief Financial Officer (Upto 13th November, 2019);
3. Mr. Raghav Agrawal : Chief Financial Officer (w.e.f. 14th November, 2019);
4. Ms. Perna Kakkar : Company Secretary & Compliance Officer.

During the Financial Year, the Nomination and Remuneration Committee, Audit Committee and the Board of Directors at their respective meetings held on 13th November, 2019, has approved the appointment of Mr. Raghav Agrawal (DIN: 02264149) as Chief Financial Officer (CFO), Key Managerial Personal of the Company w.e.f. 14th November, 2019 in addition to his continued directorship on the Board of the Company as Non-Executive Non Independent Director of the Company w.e.f. 21st May, 2019.

Mr. Dinesh Jain (DIN: 00216803), Chief Financial Officer (CFO), Key Managerial Personal of the Company, resigned from the Board w.e.f. 14th November, 2019 due to his personal preoccupations. The Board of Directors placed on record his appreciation for the assistance and valuable guidance during his tenure as CFO of the Company.

20. BOARD'S COMPOSITION AND INDEPENDENCE:

Your Company's Board consists of leaders and visionaries who provide strategic direction and guidance to the organization. As on 31st March 2020, the Board comprises of One Executive Director, two Non-Executive Non-Independent Directors and three Independent Directors.

The Company has received necessary declarations from each of the Independent Director that they continue to meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulations 16(1)(b) & 25 of the Listing Regulations and that they are not debarred from holding the office of director by virtue of any SEBI order or any other such authority. All the Independent Directors have confirmed that they are in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, with respect to registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs.

21. COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES:

The Company has adopted a Remuneration Policy for the Directors, Key Managerial Personnel and other employees, pursuant to Section 178(3) of the Companies Act, 2013. The broad parameters covered under the Policy are - Company Philosophy, Guiding Principles, Nomination of Directors, Remuneration of Directors, Nomination and Remuneration of the Key Managerial Personnel and the Remuneration of Other Employees and is based on the commitment of fostering a culture of leadership with trust.

Pursuant to Section 134(3) of the Companies Act, 2013, the Nomination and Remuneration policy of the Company is available on the Company's website i.e. <https://kashyaptele-medicines.com>. It is affirmed that the remuneration paid to Directors, Key Managerial Personnel and all other employees is as per the Remuneration Policy of the Company.

22. AUDITORS:

(a) Statutory Auditors and Auditor's Report:

As per the provisions of Sections 139, 142 and all other applicable provisions of the Companies Act, 2013, at the 23rd Annual General Meeting of the Company held on 18th September, 2017, the Members of the Company had appointed M/s. Saremal & Company, Chartered Accountants (Firm Registration No. 109281W), as the Statutory Auditors of the Company to hold the office for a term of 5 (five) years from the conclusion of 23rd Annual General Meeting till the conclusion of the 28th Annual General Meeting to be held in the year 2022.

Further the Ministry of Corporate Affairs (MCA) vide notification dated 7th May, 2018 has done away with the requirement of ratification of appointment of Statutory Auditors at every Annual General Meeting, as per the first proviso of Section 139 of the Companies Act, 2013 and the Companies (Audit and Auditors) Amendment Rules, 2018. Accordingly, the Company is not required to pass any resolution pertaining to ratification of the appointment of Statutory Auditors in the Annual General Meeting and thus the said agenda does not forms the part of the notice to the said Annual General Meeting.

The Statutory Auditors' report annexed to the financial statement for the Financial Year 2019-2020 does not contain any qualification, reservation or adverse remark and is self-explanatory and unmodified and thus does not require any further clarifications/ comments.

(b) Secretarial Auditors:

Pursuant to Section 204 of the Companies Act, 2013 read with Rule 9 of the Companies (Appointment and

Remuneration of Managerial Personnel) Rules, 2014, the Board had appointed M/s. SPANJ & Associates, Practicing Company Secretaries, Ahmedabad as Secretarial Auditors of the Company for the Financial Year 2019-2020 to conduct Secretarial Audit and the Secretarial Audit Report in Form MR-3 as furnished by him and as annexed herewith as **Annexure-C** which forms an integral part of this Report and which does not contain any qualification, reservation or adverse remark and is self-explanatory and thus does not require any further clarifications / comments.

Further, the Board of Directors in its board meeting held on 26th June, 2020, has appointed M/s. SPANJ & Associates, Company Secretaries, Ahmedabad as the Secretarial Auditors of the Company for the Financial Year 2020-2021. Further the Company has received consent letter regarding such appointment in accordance with the applicable provisions of the Companies Act and rules framed thereunder.

(c) Internal Auditors:

The Board of Directors has appointed M/s. Jagdish Verma & Co., Chartered Accountants, Ahmedabad (FRN: 103837W) as an Internal Auditors of the Company for the Financial Year 2020-2021 in their Meeting held on 26th June, 2020.

As regards the comments made in the Auditor's Report, the Board is of the opinion that they are self-explanatory and does not require any further clarification.

23. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENT UNDER SECTION 186 OF THE COMPANIES ACT 2013:

The details of Loans, Guarantee and Investments covered under the provisions of Section 186 of the Companies Act, 2013 and as applicable to the Company are given in the notes to the Financial Statements.

24. MANAGEMENT DISCUSSION AND ANALYSIS:

As per requirements of Regulation 34 of Listing Regulations, the Management's Discussion and Analysis report of the Company is annexed as **Annexure-D** which forms an integral part of this Report.

25. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES REFERRED TO IN SUB-SECTION (1) OF SECTION 188 OF THE COMPANIES ACT, 2013:

All transactions with related parties were in the ordinary course of business and on arm's length basis. The Company has not entered into any transaction of a material nature with any of the related parties which are in conflict with the interest of the Company.

All transactions with related parties were periodically reviewed and approved by the Audit Committee. Further, there were no transactions with related parties which qualify as material

transactions under the Regulations 23 of the Listing Regulations.

Pursuant to Section 134(3)(h) of the Companies Act, 2013, a statement showing particulars as "Not Applicable" of contracts and arrangements with related parties under Section 188(1) of the Companies Act, 2013 is annexed to the this Report as **Annexure-E** in the prescribed Form-AOC-2.

The details of related party transactions are disclosed in Note No. 29 of the notes to the financial statement forming part of the Annual Reports.

26. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

(A) Conservation of energy and Technology absorption

The particulars as required under the provisions of Section 134 (3)(m) of the Companies Act, 2013 in respect of conservation of energy and technology absorption have not been furnished considering the nature of activities undertaken by the Company during the year under review.

(B) Foreign exchange earnings and Outgo

There were no foreign exchange earnings and outgo during the year under review.

27. REPORT ON RISK MANAGEMENT POLICY:

The Company has laid down a Risk Management Policy and identified threat of such events which if occurs will adversely affect either/or, value to shareholders, ability of Company to achieve objectives, ability to implement business strategies, the manner in which the Company operates and reputation as "Risks". Further such Risks are categorized in to Strategic Risks, Operating Risks & Regulatory Risks. A detailed exercise is carried out to identify, evaluate, manage and monitoring all the three types of risks.

28. DEPOSITS:

During the period under report, the Company has not accepted any deposits from the public falling within the purview of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

29. ANNUAL EVALUATION BY THE BOARD OF ITS OWN PERFORMANCE AND THAT OF ITS COMMITTEES AND INDIVIDUAL DIRECTORS

Pursuant to the provisions of Section 134 (3)(p) of the Companies Act, 2013 and Regulation 19 of Listing Regulations, the Board has carried out the annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working of its various committees as per the criteria laid down by the Nomination and Remuneration Committee. An indicative list of factors on which evaluation of the individual directors, the Board and the Committees was carried out includes profile, experience, contribution of each Director to

the growth of the Company, board structure and composition, dedication, knowledge, sharing of information with the Board, regular attendance, preparedness & participation, team work, decision making process, Board culture and dynamics, independence, governance, ethics and values, adherence to corporate governance norms, quality of relationship between the Board and Management, their roles, rights, responsibilities in the Company.

In addition, pursuant to the provisions of Schedule IV to the Companies Act, 2013 the Independent Directors reviewed the performance of the Non-Independent Directors and of the Board as a whole, performance of the Chairman of the Board taking into account the views of all the Directors and the quality, quantity and timeliness of flow of information between the Company management and the Board and its sufficiency for the Board to effectively perform its duties.

Separate meeting of Independent Directors: of the Company was held on 07th February, 2020 and it reviewed the performance of Non-Independent Directors & the Board as a whole and also reviewed the performance of Chairman of the Company. The same was discussed in the board meeting that followed the meeting of the Independent Directors, at which the performance

of the Board, its committees and individual Directors was also discussed.

30. COMMITTEES OF THE BOARD:

The Company's Board has the following Committees:

- I. Audit Committee
- II. Stakeholders Relationship Committee
- III. Nomination and Remuneration Committee

I. AUDIT COMMITTEE

The Audit Committee is constituted in accordance with the provisions of Regulation 18 of the Listing Regulations and Section 177 of the Companies Act, 2013. The powers, role and terms of reference of the Audit Committee covers the areas as contemplated under Section 177 of the Companies Act, 2013 and Regulation 18 of Listing Regulations, as applicable, besides other terms as referred by the Board of Directors.

During the year, the Audit Committee met four times on 20th May, 2019, 02nd August, 2019, 13th November, 2019 and 07th February, 2020. The maximum gap between two meetings was less than one hundred and twenty days.

Name of Members	Designation	Category	Attendance at the Audit Committee Meetings Held on			
			20 th May, 2019	02 nd August, 2019	13 th November, 2019	7 th February, 2020
Ms. Surabhi Agrawal*	Chairperson	Independent Director	√	√	√	√
Mr. Girwarsingh Shekhawat	Member	Independent Director	√	Resigned w.e.f. 21 st May, 2019		
Mr. Dinesh Jain	Member	Non-Executive Non-Independent Director	√	Resigned w.e.f. 21 st May, 2019		
Mr. Mayank Khetan [§]	Member	Independent Director	NA	√	√	√
Mr. Raghav Agrawal [§]	Member	Non-Executive Non-Independent Director	NA	√	√	√
Mr. Devkinandan Sharma**	Chairperson	Independent Director	NA	NA	NA	NA

[§]Appointed as committee member w.e.f. 21st May, 2019

* Resigned as committee Chairperson w.e.f. 8th February, 2020

** Appointed as committee Chairperson w.e.f. 8th February, 2020

TERMS OF REFERENCE OF AUDIT COMMITTEE:

1. Oversight of the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
2. Recommendation for appointment, remuneration and terms of appointment of auditors of the company;
3. Approval of payment to statutory auditors for any other services rendered by the statutory auditors;

4. Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 - a. Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of section 134 of the Companies Act, 2013
 - b. Changes, if any, in accounting policies and practices and reasons for the same

- c. Major accounting entries involving estimates based on the exercise of judgment by management
 - d. Significant adjustments made in the financial statements arising out of audit findings
 - e. Compliance with listing and other legal requirements relating to financial statements
 - f. Disclosure of any related party transactions
 - g. Qualifications in the draft audit report
5. Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
 6. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
 7. Review and monitor the auditor's independence and performance, and effectiveness of audit process;
 8. Approval or any subsequent modification of transactions of the company with related parties;
 9. Scrutiny of inter-corporate loans and investments;
 10. Valuation of undertakings or assets of the company, wherever it is necessary;
 11. Evaluation of internal financial controls and risk management systems;
 12. Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
 13. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
 14. Discussion with internal auditors of any significant findings and follow up there on;
 15. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
 16. Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
 17. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
 18. To review the functioning of the Whistle Blower mechanism;
 19. Approval of appointment of CFO (i.e., the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
 20. Reviewing the Management letters/ letters of Internal Control weaknesses issued by Statutory Auditor;
 21. Review of Management discussion and analysis of financial condition and results of operations;
 22. Review of Statement of significant related party transactions (as defined by the Audit Committee), submitted by management;
 23. Review of Management letters / letters of internal control weaknesses issued by the statutory auditors;
 24. Review of Internal audit reports relating to internal control weaknesses;
 25. Review of appointment, removal and terms of remuneration of the Chief internal auditor; and
 26. Carrying out any other function as may be required in pursuance of the decision of the Board of Directors of the Company or any provision under the Companies Act or Listing Regulations or any other applicable law.
- II. STAKEHOLDERS RELATIONSHIP COMMITTEE**
- Stakeholders Relationship Committee of the Company is constituted in line with the provisions of Section 178 of the Companies Act, 2013 and Regulation 20 of the Listing Regulations. The Board has constituted Stakeholders' Relationship Committee inter alia, to consider and review the complaints received from shareholders like transfer of shares, non- receipt of balance sheet etc.

During the year, the Committee met four times on 20th May, 2019, 02nd August, 2019, 13th November, 2019 and 7th February, 2020. The composition of the Committee as well as the particulars of attendance at the Committee meetings are given below:

Name of Members	Designation	Category	Attendance at the Stakeholders Relationship Committee Meetings Held on			
			20 th May, 2019	02 nd August, 2019	13 th November, 2019	7 th February, 2020
Mr. Girwarsingh Shekhawat	Chairperson	Independent Director	√	Resigned w.e.f. 21 st May, 2019		
Mr. Amit Agrawal	Member	Managing Director	√	√	√	√
Mr. Dinesh Jain	Member	Non-Executive Non-Independent Director	√	Resigned w.e.f. 21 st May, 2019		
Mr. Raghav Agrawal [§]	Chairperson	Non-Executive Non-Independent Director	NA	√	√	√
Mr. Mayank Khetan [§]	Member	Independent Director	NA	√	√	√

[§]Appointed as committee member/Chairperson w.e.f. 21st May, 2019

TERMS OF REFERENCE OF STAKEHOLDERS RELATIONSHIP COMMITTEE:

1. To attend to requests from the shareholders for transfer / transmission of shares and all matters incidental or related thereto;
2. To attend to matters relating dematerialization / rematerialisation of shares / other securities and all matters incidental or related thereto;
3. To advise the Board on matters incidental or relating to issue of Bonus Shares & Rights Shares, etc.;
4. To consider and resolve grievances of the security holders of the Company, including complaints related to the transfer of shares, non-receipt of annual report and non-receipt of declared dividends, general meetings etc.;
5. To investigate complaints relating to allotment of shares, approval of transfer or transmission of shares or any other securities;
6. To attend to issue of duplicate certificates and new certificates on split / consolidation / renewal;
7. To review measures taken for effective exercise of voting rights by shareholders;

8. To review adherence to the standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
9. To review of the measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/ annual reports/statutory notices by the shareholders of the Company;
10. To attend to matters relating to compliance with the Listing Regulations and other statutory requirements concerning the interests of holders of shares and other securities; and
11. To carry out any other function as may be required in pursuance of the decision of the Board of Directors of the Company or any provision under the Companies Act or Listing Regulations or any other applicable law.

III. NOMINATION AND REMUNERATION COMMITTEE AND POLICY THEREON

The Nomination and Remuneration Committee of the Company is constituted in alignment with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of the Listing Regulations and terms of reference, including role & powers of the Committee as referred by the Board of Directors.

During the year, the Nomination and Remuneration Committee met four times on 20th May, 2019, 13th July, 2019, 13th November, 2019 and 7th February, 2020.

Name of Members	Designation	Category	Attendance at the Nomination and Remuneration Committee Meeting Held on			
			20 th May, 2019	13 th July, 2019	13 th November, 2019	7 th February, 2020
Ms. Surabhi Agrawal*	Chairperson	Independent Director	√	√	√	√
Mr. Girwarsingh Shekhawat	Member	Independent Director	√	Resigned w.e.f. 21 st May, 2019		
Mr. Dinesh Jain	Member	Non-Executive Non-Independent Director	√	Resigned w.e.f. 21 st May, 2019		
Mr. Mayank Khetan [§]	Member	Independent Director	NA	×	√	√
Mr. Raghav Agrawal [§]	Member	Non-Executive Non-Independent Director	NA	√	√	√
Mr. Devkinandan Sharma**	Chairperson	Independent Director	NA	NA	NA	NA

[§]Appointed as committee member w.e.f. 21st May, 2019

* Resigned as committee Chairperson w.e.f. 8th February, 2020

** Appointed as committee Chairperson w.e.f. 8th February, 2020

TERMS OF REFERENCE OF NOMINATION & REMUNERATION COMMITTEE:

- Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommending to the Board a policy, relating to the remuneration of the directors, key managerial personnel and other employees;
- Formulating of criteria for evaluation of performance of the independent directors and the Board;
- Devising a policy on Board diversity;
- Identifying persons who qualify to become directors and who may be appointed in senior management in accordance with the criteria laid down, recommending to the Board their appointment and removal;
- Determining whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;
- Recommend to the board, all remuneration, in whatever form, payable to senior management;
- Analyzing, monitoring and reviewing various human resource and compensation matters; and
- Determining the company's policy on specific remuneration packages for executive directors including pension rights and any compensation payment, and determining remuneration packages of such directors.

Policy for selection and appointment of Directors and Key Managerial Personnel and their remuneration

The Nomination and Remuneration Committee (NRC) has adopted a Charter which, inter alia, deals with the manner of selection of Board of Directors and Key Managerial Personnel and their remuneration.

A. Appointment criteria and qualifications:

- The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and recommend to the Board his / her appointment.
- A person should possess adequate qualification, expertise and experience for the position he / she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person are sufficient / satisfactory for the concerned position.
- The Company shall not appoint or continue the employment of any person as Whole-time Director who has attained the age of 70 years. Provided that the term of the person holding this position may be extended beyond the age of seventy years with the approval of shareholders by passing a special resolution based on the explanatory statement annexed to the notice for such motion indicating the justification for extension of appointment beyond 70 years.

- **Term / Tenure:**

1. **Managing Director/Whole-time Director:**

The Company shall appoint or re-appoint any person as its Executive Chairman, Managing Director or Executive Director for a term not exceeding five years at a time. No re-appointment shall be made earlier than one year before the expiry of term.

2. **Independent Director:**

An Independent Director shall hold office for a term up to five consecutive years on the Board of the Company and will be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in the Board's report. No Independent Director shall hold office for more than two consecutive terms, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director. Provided that an Independent Director shall not, during the said period of three years, be appointed in or be associated with the Company in any other capacity, either directly or indirectly. However, if a person who has already served as an Independent Director for five years or more in the Company as on 1st October, 2014 or such other date as may be determined by the Committee as per regulatory requirement, he / she shall be eligible for appointment for one more term of five years only. - At the time of appointment of Independent Director it should be ensured that, no such Director should serve as an Independent Director in more than seven listed entities, further any Director who is serving as a Whole-time Director in any listed entity shall serve as an Independent Director in not more than 3 listed entities.

- **Evaluation:**

During the year under review, the Committee shall carry out evaluation of performance of every Director, KMP and Senior Management Personnel.

- **Removal:**

Due to reasons for any disqualification mentioned in the Companies Act, 2013, rules made there under, the Committee may recommend, to the Board with reasons recorded in writing, removal of a Director, KMP or Senior Management Personnel subject to the provisions and compliance of the said Act, rules and regulations.

- **Retirement:**

The Director, KMP and Senior Management Personnel shall retire as per the applicable provisions of the Companies Act, 2013 and the prevailing policy of the Company. The Board will have the discretion to retain the Director, KMP, Senior Management Personnel in the same position / remuneration or otherwise even after attaining the retirement age, for the benefit of the Company.

B. Remuneration Policy

1. The remuneration / compensation / commission etc. to the Whole-time Director, KMP and Senior Management Personnel will be determined by the Committee and recommended to the Board for approval. The remuneration / compensation / commission etc. shall be subject to the prior/post approval of the shareholders of the Company and Central Government, wherever required.
2. The remuneration and commission to be paid to the Whole-time Director shall be in accordance with the percentage / slabs / conditions laid down in the Articles of Association of the Company and as per the provisions of the Companies Act, 2013, and the rules made thereunder.
3. Increments to the existing remuneration / compensation structure may be recommended by the Committee to the Board which should be within the slabs approved by the Shareholders in the case of Whole-time Director. Increments will be effective from 1st April unless otherwise decided by the board.
4. Where any insurance is taken by the Company on behalf of its Whole-time Director, Chief Executive Officer, Chief Financial Officer, the Company Secretary and any other employees for indemnifying them against any liability, the premium paid on such insurance shall not be treated as part of the remuneration payable to any such personnel. Provided that if such person is proved to be guilty, the premium paid on such insurance shall be treated as part of the remuneration.

- **Remuneration to Whole-time / Executive / Managing Director, KMP and Senior Management Personnel:**

1. **Fixed pay:**

The Whole-time Director / KMP and Senior Management Personnel shall be eligible for a monthly remuneration as may be approved by the Board on the recommendation of the Committee. The breakup of the pay scale and quantum of perquisites including, employer's contribution to P.F, pension scheme, medical expenses, club fees etc. shall be decided and approved by the Board on the recommendation of the Committee and approved by the shareholders and Central Government, wherever required.

2. **Minimum Remuneration:**

If, in any financial year, the Company has no profits or its profits are inadequate, the Company shall pay remuneration to its Managing Director and Whole-time Directors in accordance with the provisions of Schedule V of the Companies Act, 2013 and if it is not able to comply with such provisions, with the previous approval of the Central Government.

3. Provisions for excess remuneration:

If any Whole-time Director draws or receives, directly or indirectly by way of remuneration any such sums in excess of the limits prescribed under the Companies Act, 2013 or without the prior sanction of the Central Government, where required, he / she shall refund such sums to the Company and until such sum is refunded, hold it in trust for the Company. The Company shall not waive recovery of such sum refundable to it unless permitted by the Central Government.

• Remuneration to Non- Executive / Independent Director:

1. Remuneration / Commission:

The remuneration / commission shall be fixed as per the slabs and conditions mentioned in the Articles of Association of the Company and the Companies Act, 2013 and the rules made thereunder.

2. Sitting Fees:

The Non- Executive / Independent Director may receive remuneration by way of fees for attending meetings of Board or Committee thereof. Provided that the amount of such fees shall not exceed One Lakh Rupees per meeting of the Board or Committee or such amount as may be prescribed by the Central Government from time to time.

3. Commission:

Commission may be paid within the monetary limit approved by shareholders, subject to the limit not exceeding 1% of the profits of the Company computed as per the applicable provisions of the Companies Act, 2013.

31. VIGIL MECHANISM:

In compliance with the provisions of Section 177 (10) of the Companies Act, 2013 and Regulation 22 of the Listing Regulations, the Company has a well established Vigil Mechanism/ Whistle Blower Policy for providing a formal mechanism for all employees of the Company to approach Chairman of the Audit Committee of the Company and make protective disclosures about the unethical behavior, actual or suspected fraud and violation of the Company's Code of Conduct and Business Ethics. Under the Policy, each employee of the Company has an assured access to the Chairman of the Audit Committee. The Vigil Mechanism/Whistle Blower Policy is displayed on the website of the Company i.e. www.kashyaptelemedicines.com.

32. CODE OF CONDUCT:

Pursuant to Regulations 8 & 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015; your Company has formulated, implemented and has in place a comprehensive "Code of Fair

Disclosure of Unpublished Price Sensitive Information" & "Code of Conduct for Prevention of the Insider Trading" (hereinafter known as "Codes of Conduct") for regulating, monitoring and reporting the trading by Designated persons of the Company which include Promoters, Directors, Heads and such other employees of the Company and others who are expected to have access to unpublished price sensitive information and as may be defined under the "Codes of Conduct".

33. INTERNAL CONTROL SYSTEMS:

The Company has in place adequate internal financial controls with reference to financial statements. The Board has adopted policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of fraud, error reporting mechanisms, the accuracy and completeness of the accounting records and the timely preparation of reliable financial disclosures.

The Company has devised systems to ensure compliance with the provisions of all applicable laws to the Company. During the year under review, the Audit Committee, the Statutory Auditors and top management of the Company has ensured and reviewed the adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company. Significant Audit observations and corrective actions, if any, thereon were presented before the Board for their review.

34. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES:

The Company is not falling under the criteria as mentioned in Section 135 of the Companies Act, 2013 read with Companies (Corporate Social Responsibility Policy) Rules, 2014. Hence, provision of Corporate Social Responsibility is not applicable to the Company.

35. DISCLOSURE FOR APPLICABILITY OF COMPANIES (COST RECORDS AND AUDIT) RULES, 2014 UNDER THE COMPANIES ACT 2013:

The provisions of the Section 148 read with Companies (Cost Records and Audit) Rules, 2014 of the Companies Act, 2013 is not applicable on the Company and thus the Company is not required to maintain the Cost Records.

36. CORPORATE GOVERNANCE REPORT:

Pursuant to Regulations 15 and 34(3) read with Schedule V of Listing Regulations, a Report on Corporate Governance is not applicable to the Company for the Financial Year 2019-2020 as the paid up equity share capital and net worth of the Company does not exceed ₹ 10 crores and ₹ 25 crores respectively as on the last day of previous Financial Year ended on 31st March, 2019.

37. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

The BSE Limited (BSE) vide its letter dated 27th February, 2015, trading in securities of the Company have been suspended due to various reasons w.e.f. 4th March, 2015. The management of the Company had promptly initiated contact with BSE officials in the said matter and continuous representations are being made to BSE in regards to revocation of suspension. The revocation of suspension is under process and expected to be completed soon.

No other significant and material orders passed by the Regulators or Courts or Tribunals impacting the going concern status and Company's operations in Future.

38. SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place, policy on Prevention, Prohibition and Redressal of Sexual Harassment for women at workplace in accordance with the requirements of The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The policy has set guidelines on the redressal and enquiry process that is to be followed by complainants, whilst dealing with issues related to sexual harassment at the work place. During the year, the Company has neither received any complaints nor has any pending complaints under the said Act.

39. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to Sections 134(3)(c) and 134(5) of the Companies Act, in relation to Financial Statements of the Company for the year ended 31st March, 2020, the Board of Directors states that:

- a) in the preparation of the annual accounts for the Financial Year ended 31st March, 2020, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;
- c) the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) the Directors had prepared the annual accounts on a going concern basis;

- e) the proper internal financial controls were in place and that the financial controls were adequate and were operating effectively; and
- f) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

40. LISTING OF SHARES:

The Equity Shares of the Company are listed on the BSE Limited (BSE) with scrip code No. 531960. The annual listing fee for the Financial Year 2020-2021 has been paid to BSE Limited. Further, the Company complies with the provisions of the Listing Regulation on a regular basis.

41. COMPLIANCE WITH SECRETARIAL STANDARDS ISSUED BY THE INSTITUTE OF COMPANY SECRETARIES OF INDIA (ICSI):

The Company is compliant with and ensures compliance under the provisions of the applicable Secretarial Standards issued by the ICSI.

42. NON APPLICABILITY OF GOODS AND SERVICE TAX (GST):

As per the Central Governments guidelines on Goods and Service Tax (GST) which has become effective w.e.f. 1st July, 2017 and read with Notification No. 10/2019-Central Tax dated 7th March, 2019 w.e.f. 01st April, 2019 with respect to the enhancement of threshold limit of turnover for registration under Goods and Service Tax (GST) to ₹ 40 Lakhs for sale of goods and ₹ 20 Lakhs for sale of services. Accordingly, the Company does not fall under the applicability criteria of registration under GST.

43. ACKNOWLEDGEMENT:

This Financial Year has seen the outbreak of a global pandemic which has sent tremors in all sectors of the economy. Your Company is no exception and is fighting the adversities. Our employees at all levels, have been core to our existence and their hard work, co-operation and support is helping the Company to face all challenges. Our Company is always grateful for their efforts. Your Directors are highly grateful for all the guidance, support, assistance and co-operation received from the Stakeholders, Business Partners, Government & other Statutory Bodies, Banks, Financial Institutions, Shareholders, Esteemed Customers and Suppliers during the year under review. The Company deeply acknowledges their support and guidance.

**On behalf of Board of Directors
For, Kashyap Tele-Medicines Limited**

Sd/-

Amit Agrawal

Managing Director

DIN: 00169061

Date : 7th August, 2020

Place: Ahmedabad

ANNEXURE – A TO DIRECTORS’ REPORT : FORM NO. MGT 9

EXTRACT OF ANNUAL RETURN
As on the Financial Year ended on 31st March, 2020
[Pursuant to Section 92 (3) of the Companies Act, 2013 and Rule 12(1)
of the Company (Management & Administration) Rules, 2014]

I. REGISTRATION & OTHER DETAILS:

CIN	L29110MH1995PLC085738
Registration Date	20 th February, 1995
Name of the Company	KASHYAP TELE-MEDICINES LIMITED
Category/Sub-category of the Company	Company Limited by Shares/ Indian Non- Government Company
Address of the Registered office & contact details	2 nd Floor, Pushpaawati building No. 2, Chandanwadi, Girgaon Road, Mumbai – 480 002 E-mail ID :- investor.relations@kashyaptele-medicines.com Website : www.kashyaptele-medicines.com
Whether listed company	YES (BSE Limited)
Name, Address & contact details of the Registrar & Transfer Agent, if any.	Link Intime India Private Limited 5 th floor, 506 to 508 Amarnath Business Centre - I (ABC - I), Beside Gala Business Centre, Nr. St. Xavier's College Corner, Off C G Road, Ellisbridge, Ahmedabad, Gujarat, 380006 Phone :- 079-26465179 E-mail ID : ahmedabad@linkintime.co.in Website : www.linkintime.co.in

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

(All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

Sr. No.	Name and Description of main products / services	NIC Code of the Product/ service **	% to total turnover of the Company
1	Other Information Technologies & Computer Services activities and software sale	62099, 47413	100

** Source: National Industrial Classification (NIC -2008)

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

Sr. No.	Name and Address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of Shares held	Applicable Section
NIL					

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity):**(A) Category-wise Share Holding**

Category of Shareholders		No. of Shares held at the beginning of the year [As on 1 st April, 2019]				No. of Shares held at the end of the year [As on 31 st March, 2020]				% Change during the year
		Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters										
(1) Indian										
a) Individual/ HUF	2457900	0	2457900	5.15	2457900	0	2457900	5.15	0.00	
b) Central Govt	0	0	0	0.00	0	0	0	0.00	0.00	
c) State Govt(s)	0	0	0	0.00	0	0	0	0.00	0.00	
d) Bodies Corp.	14915000	0	14915000	31.25	14915000	0	14915000	31.25	0.00	
e) Banks / FI	0	0	0	0.00	0	0	0	0.00	0.00	
f) Any other	0	0	0	0.00	0	0	0	0.00	0.00	
Total shareholding of Promoter (A)	17372900	0	17372900	36.40	17372900	0	17372900	36.40	0.00	
B. Public Shareholding										
1. Institutions										
a) Mutual Funds	0	0	0	0.00	0	0	0	0.00	0.00	
b) Banks / FI	27000	0	27000	0.06	27000	0	27000	0.06	0.00	
c) Central Govt	0	0	0	0.00	0	0	0	0.00	0.00	
d) State Govt(s)	0	0	0	0.00	0	0	0	0.00	0.00	
e) Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00	
f) Insurance Companies	0	0	0	0.00	0	0	0	0.00	0.00	
g) FIs	0	0	0	0.00	0	0	0	0.00	0.00	
h) Foreign Venture Capital Funds	0	0	0	0.00	0	0	0	0.00	0.00	
i) Others (specify)	0	0	0	0.00	0	0	0	0.00	0.00	
Sub-total (B)(1):-	27000	0	27000	0.06	27000	0	27000	0.06	0.00	
2. Non-Institutions										
a) Bodies Corp.										
i) Indian	14343455	0	14343455	30.06	14210620	0	14210620	29.78	-0.28	
ii) Overseas	0	0	0	0	0	0	0	0	0	
b) Individuals	0	0	0	0	0	0	0	0	0	
i) Individual shareholders holding nominal share capital upto ₹ 1 lakh	11154860	36030	11190890	23.45	11183437	36030	11219467	23.51	0.06	
ii) Individual shareholders holding nominal share capital in excess of ₹ 1 lakh	4272457	0	4272457	8.95	4428534	0	4428534	9.28	0.33	
c) Qualified Foreign Investor	0	0	0	0	0	0	0	0	0	
(d) Others (specify)	0	0	0	0	0	0	0	0	0	
Non Resident Indians (Non Repat)	30585	0	30585	0.06	34085	0	34085	0.07	-0.01	
Non Resident Indians (Repat)	39523	0	39523	0.08	39523	0	39523	0.08	0.00	
Overseas Corporate Bodies	0	0	0	0	0	0	0	0	0	
Foreign Nationals	0	0	0	0	0	0	0	0	0	
Clearing Members	65724	0	65724	0.14	12400	0	12400	0.03	-0.11	
Trusts	2000	0	2000	0.00	2000	0	2000	0.00	0.00	
HUF	377466	0	377466	0.791	375471	0	375471	0.787	-0.004	
Foreign Bodies - DR	0	0	0	0	0	0	0	0	0	
Sub-total (B)(2):-	30286070	36030	30322100	63.54	30286070	36030	30322100	63.54	0.00	
Total Public Shareholding (B)= (B)(1)+ (B)(2)	30313070	36030	30349100	63.60	30313070	36030	30349100	63.60	0.00	
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0	
Grand Total (A+B+C)	47685970	36030	47722000	100.00	47685970	36030	47722000	100.00	0.00	

B) Shareholding of Promoter:

Sr. No.	Shareholder's Name	Shareholding at the beginning of the year [As on 1 st April, 2019]			Shareholding at the end of the year [As on 31 st March, 2020]			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	M/s. Jindal Worldwide Limited	14915000	31.25	0.00	14915000	31.25	0.00	0.00
2	Mr. Jitendra Tarachand Agrawal	749900	1.57	0.00	749900	1.57	0.00	0.00
3	Mr. Amit Yamunadutt Agarwal	500000	1.05	0.00	500000	1.05	0.00	0.00
4	Late Mrs. Sarbatidevi Agrawal	500000	1.05	0.00	500000	1.05	0.00	0.00
5	Mr. Radheshyam T Agrawal	357000	0.75	0.00	357000	0.75	0.00	0.00
6	Dr. Yamunadutt Amilal Agrawal	351000	0.74	0.00	351000	0.74	0.00	0.00
	Total	17372900	36.40	0.00	17372900	36.40	0.00	0.00

C) Change in Promoters' Shareholding (There is no change in Promoters' Shareholding during the year):

Sr. No.	Particulars	Shareholding at the beginning of the year [As on 1 st April, 2019]		Date wise increase / decrease in share holding during the year specifying the reasons for increase /decrease (e.g. Allotment / transfer / bonus/ sweat equity etc.):	Cumulative shareholding at the end of the year [As on 31 st March 2020]	
		No. of Shares	% of total shares of the company		No. of Shares	% of total shares of the company

NIL

D) Shareholding Pattern of top ten Shareholders: (Other than Directors, Promoters and Holders of GDRs and ADRs):

Sr. No.	Top 10 shareholders	Shareholding at the beginning of the year [As on 1 st April, 2019]		Date wise increase/ decrease in shareholding during the year	Increase/ Decrease in Shareholding	Reason	Cumulative shareholding at the end of the year [As on 31 st March 2020]	
		No. of Shares held	% of total shares of the company				No. of Shares held	% of total shares of the company
1.	Amitara Industries Private Limited	12380751	25.94	-	-	-	12380751	25.94
2.	Snehal Overseas Private Limited	1108020	2.32	-	-	-	1108020	2.32
3.	Kailash T Agrawal	820000	1.72	-	-	-	820000	1.72
4.	Mit Desai	410000	0.86	-	-	-	410000	0.86
5.	Hitesh Karnawat	394423	0.83	-	-	-	394423	0.83
6.	Anup Kumar Singhania	342500	0.72	-	-	-	342500	0.72
7.	Rishab Kumar Jain	335000	0.70	-	-	-	335000	0.70
8.	Sushila Devi Lalit Kumar Karnawat	321091	0.67	-	-	-	321091	0.67
9.	Shrinathji Dye Chem Export Private Limited	250000	0.52	-	-	-	250000	0.52
10.	Kunal Kirtikant Nanavati	240000	0.50	-	-	-	240000	0.50

Notes:

1. Paid up Share Capital of the Company (Face Value ₹ 1/-) at the end of the year is ₹ 4,77,22,000/-.
2. The details of holding have been clubbed based on PAN.
3. % of total Shares of the Company is based on the paid up Capital of the Company at the end of the Year.

E) Shareholding of Directors and Key Managerial Personnel:

Sr. No.	Shareholding of each directors and each key managerial personnel	Shareholding at the beginning of the year [As on 1 st April, 2019]		Date wise increase / decrease in share holding during the year specifying the reasons for increase /decrease (e.g. Allotment / transfer / bonus/ sweat equity etc.):	Cumulative shareholding at the end of the year [As on 31 st March 2020]	
		No. of Shares	% of total shares of the company		No. of Shares	% of total shares of the company
1.	Mr. Amit Agrawal	500000	1.05	-	500000	1.05

V. INDEBTEDNESS -Indebtedness of the Company including interest outstanding/accrued but not due for payment.

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the Financial Year				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	0	0	0	0
Change in Indebtedness during the financial year	0	0	0	0
* Addition	0	0	0	0
* Reduction	0	0	0	0
Net Change	0	0	0	0
Indebtedness at the end of the Financial Year	0	0	0	0
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	0	0	0	0

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-**A. Remuneration to Managing Director, Whole-time Directors and/or Manager:**

Sr. No.	Particulars of Remuneration	Name of MD/WTD/-Manager				Total Amount
		Mr. Amit Agrawal				
1	Gross salary	-	-	-	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-	-	-
2	Stock Option	-	-	-	-	-
3	Sweat Equity	-	-	-	-	-
4	Commission - as % of profit - others, specify...	-	-	-	-	-
5	Others, please specify	-	-	-	-	-
	Total (A)	-	-	-	-	-
	Ceiling as per the Act	-	-	-	-	-

B. Remuneration to other directors:

Sr. No.	Particulars of Remuneration	Name of Directors				Total Amount
1	Independent Directors	Ms. Surabhi Agrawal	Mr. Devkinandan Sharma	Mr. Girwarsingh Shekhawat (Upto 20th May, 2019)	Mr. Mayank Khetan (w.e.f. 21st May, 2019)	-
	Fee for attending board committee meetings	-	-	-	-	-
	Commission	-	-	-	-	-
	Others, please specify	-	-	-	-	-
	Total (1)	-	-	-	-	-
2	Other Non-Executive Directors	Ms. Amrita Khetan	Mr. Dinesh Jain (Upto 20th May, 2019)	Mr. Raghav Agrawal (w.e.f. 21st May, 2019)	-	-
	Fee for attending board committee meetings	-	-	-	-	-
	Commission	-	-	-	-	-
	Others, please specify	-	-	-	-	-
	Total (2)	-	-	-	-	-
	Total (B)=(1+2)	-	-	-	-	-
	Total Managerial Remuneration	-	-	-	-	-
	Overall Ceiling as per the Act	-	-	-	-	-

C. Remuneration to Key Managerial Personnel other than MD/MANAGER/WT/D:

Sr. No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	CS	CFO*	Total
1	Gross salary	-	-	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	3,20,215	₹ 85,000	4,05,215
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-
	- others, specify...	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	3,20,215	85,000	4,05,215

*Total Remuneration paid to two CFO's during the Financial Year 2019-2020 is ₹ 85,000 i.e. Mr. Dinesh Jain (Upto 13th November, 2019) and Mr. Raghav Agarwal (w.e.f. 14th November, 2019).

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
B. DIRECTORS					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-
C. OTHER OFFICERS IN DEFAULT					
Penalty	-	-	-	-	-
Punishment	-	-	-	-	-
Compounding	-	-	-	-	-

ANNEXURE – B TO DIRECTORS' REPORT**PARTICULARS OF EMPLOYEES: - PURSUANT PROVISION OF SECTION 197(12) READ WITH RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014**

1	The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2019-2020.	Director's Name	Ratio to mean remuneration
		Mr. Amit Agrawal Mr. Dinesh Jain (Resigned w.e.f. 21 st May, 2019) Mr. Raghav Agarwal (Appointed w.e.f. 21 st May, 2019) Ms. Amrita Khetan Mr. Giriwarsingh Shekhawat (Resigned w.e.f. 21 st May, 2019) Mr. Mayank Khetan (Appointed w.e.f. 21 st May, 2019) Ms. Surabhi Agrawal Mr. Devkinandan Sharma	NIL (No remuneration was paid to any of the Director of the Company during the F.Y. 2019-2020)
2	The Percentage increase in remuneration of each Director, Chief Financial Officer, Company Secretary or Manager if any in the Financial Year 2019-2020.	Director's/CFO/CS	% increase in remuneration
		Director	NIL (As Point No. 1 Above)
		CFO	NIL (No increase in remuneration during the F.Y. 2019-2020)
		Company Secretary	18.29% [#]
3	Percentage increase/(decrease) in the median remuneration of employees in the Financial Year 2019-2020.	During Financial Year 2019-2020, the percentage (decrease) in the median remuneration of employees as compared to previous year was approximately (-23.67%).	
4	Number of permanent employees on the rolls of the Company.	There were 3 employees as on 31 st March, 2020.	
5	Average percentile increase in salaries of Employees other than managerial Personnel*.	The average percentile increase in salaries of Employees is 9.26% and increase in salary of Managerial Personnel during last financial year is disclosed in point no. (2) above. There was no exceptional circumstance for increase for managerial personnel in the last Financial year.	
6	Affirmation that the remuneration is as per the remuneration policy of the Company.	It is hereby affirmed that the remuneration paid during the year is as per the Remuneration Policy of the Company.	

*Managerial Personnel includes Managing Director, CFO and Company Secretary

[#]% Calculated on the basis of Net Salary Amount

ANNEXURE C – TO THE DIRECTORS' REPORT: SECRETARIAL AUDIT REPORT

FORM NO. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED ON 31st MARCH, 2020

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of

The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members

KASHYAP TELE-MEDICINES LIMITED

Regd. Off: 2nd Floor, Pushpavati Bldg,
Chandan Wadi, Mumbai – 400002 (Maharashtra)

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **KASHYAP TELE-MEDICINES LIMITED** (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives in electronic form in online system due to lockdown on account of COVID 19 during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the Financial Year ended on 31st March, 2020 has complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance- mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company as per **Annexure - A** for the Financial Year ended on 31st March, 2020 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

- (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- (d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;
- (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
- (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; and
- (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;

However, it has been found that there were no instances requiring compliance with the provisions of the laws indicated at point (c) to (h) of para (v) mentioned hereinabove during the period under review.

- VI. We further report that having regard to the compliance management system prevailing in the Company for other applicable laws, we were given to understand that there are no sector specific laws applicable to the company and therefore we have not verified compliance management system for the same.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India;
- (ii) The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

We have been informed that as per letter dated 27th February, 2015 of the BSE Limited, trading in securities of the Company had been suspended w.e.f. 4th March, 2015 due to various reasons of non compliance with listing regulations as mentioned therein. The Company has informed that they are in process of completing compliance requirements and making representation to appropriate authority for revocation of suspension of trading in securities.

We further report that as mentioned earlier, due to lapse in compliance with the certain Listing compliances as per requirement of

The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 trading of securities had been continued to be suspended during the year.

During the period under review the Company has endeavored to establish the compliance management system to adhere to the provisions of the Act, Rules, Regulations, Guidelines, Standards, mentioned hereinabove.

We have relied on the representations made by the Company and its officers for systems and mechanisms formed by the Company for compliances of the laws and regulations mentioned hereinabove as applicable to the Company.

We further report that, the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. During the year under review, it was observed that Mr. Girwarsingh Shekhawat, Non-Executive Independent Director and Mr. Dinesh Jain, Non Executive Director of the Company resigned from the Directorship of the Company & Mr. Mayank Khetan and Mr. Raghav Agrawal were appointed as an Additional Director of the Company w.e.f. 21st May, 2019. Further, company had Regularized Mr. Mayank Khetan as an Independent Director and Mr. Raghav Agrawal as a Director of the Company in AGM dated 21st August, 2019 and Re-appointed Mrs. Surabhi Agrawal as an Independent Director of the Company for the second term. Further, Mr. Dinesh Jain, CFO of the Company resigned on 14th November, 2019 and Mr. Raghav Agrawal was Appointed as Chief Financial Officer as Key Managerial Personnel as required under the provisions of Section 203 of The Companies Act, 2013 w.e.f. 14th November, 2019.

The Company has a system of sending notice to all directors to schedule the Board Meetings, agenda and detailed notes on agenda at least seven days in advance, and a system for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes, wherever required.

We further report that, the Company has endeavored to establish adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period of the Company there were no specific events / actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.

Name of Practicing C S: Ashish Doshi, Partner
SPANJ & ASSOCIATES
Company Secretaries
ACS/FCS No. : F3544
C P No. :2356

Date: 7th August, 2020
Place: Ahmedabad

P R No.: 702/2020
UDIN :F003544B000560936

Note : This report is to be read with our letter of even date which is annexed as **Annexure-B** and forms an integral part of this report.

ANNEXURE - A

List of documents verified

1. Memorandum & Articles of Association of the Company.
2. Minutes of the meetings of the Board of Directors and Committees including Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, along with attendance register held during the period under report.
3. Minutes of General Body Meetings held during the period under report.
4. Statutory Registers/Records under the Act and rules made there under made available to us for verification.
5. Declarations received from the Directors of the Company pursuant to the provisions of Section 184 of the Act.
6. Intimations/Disclosure/Declaration received from Directors under The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, if any;
7. E-Forms filed by the Company, from time-to-time, under applicable provisions of the Act and attachments thereof during the period under report.
8. Intimations / disclosures / returns filed with the Stock Exchanges pursuant to the provisions of Listing Agreement entered into by the Company with the Stock Exchange and the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 during the period under report.
9. Various policies framed by the Company from time to time as required under the Act as well as Listing Agreement and the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with circulars issued by the SEBI from time to time.

Annexure - B

To,
The Members
KASHYAP TELE-MEDICINES LIMITED
Regd. Off: 2nd Floor, Pushpavati Bldg,
Chandan Wadi, Mumbai – 400002 (Maharashtra)

Sir,

Sub: Secretarial Audit Report for the Financial Year ended on 31st March, 2020.

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

Name of Practicing C S: Ashish Doshi, Partner
SPANJ & ASSOCIATES
Company Secretaries
ACS/FCS No. : F3544
C P No. :2356
P R No.: 702/2020
UDIN :F003544B000560936

Date: 7th August, 2020
Place: Ahmedabad

ANNEXURE – D TO DIRECTORS’ REPORT: - MANAGEMENT DISCUSSION AND ANALYSIS REPORT

OVERVIEW:

Kashyap Tele-Medicines Limited (“the Company”) is engaged into Information Technologies Related Services and is engaged into the business of Software sales also. It is classified as Non-Government, public limited company incorporated in India and having its registered office in Mumbai, Maharashtra and Corporate office in Ahmedabad, Gujarat. The Company’s shares are listed with BSE Limited with a BSE Scirp Code of 531960.

These financial statements of the Company for the year ended 31st March, 2020 have been prepared in accordance with Ind AS. The Company has prepared its financial statements that comply with Ind AS. For the purposes of transition to Ind AS, the Company has followed the guidance prescribed under Ind AS 101- First Time adoption of Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with relevant Rules made thereunder.

1. INDUSTRY STRUCTURE AND DEVELOPMENT:

Software and computing technology is transforming business in every industry around the world in a profound and fundamental way. The continued reduction in the unit cost of hardware, the explosion of network bandwidth, advanced software technologies and technology enabled service are fueling the rapid digitization of business process and information. The digital revolution is cascading across industries, redefining customer expectations, enabling disruptive market offerings and automating core processes and enabling software-based disruptive market offerings and business models. This disruption is characterized by personalized user experiences, innovative products and services, increased business agility, extreme cost performance and a disintermediation of the supply chain.

India’s IT industry contributes 8% to GDP. The IT Business Process Management (BPM) industry grew 6.1% year-on-year, while the IT & ITES industry grew from \$170 Billion in Financial Year 2019 to \$181 Billion in Financial Year 2020. India has become the world’s largest digital capability hub, accounting for 75% of the global digital talent. Revenue from digital is expected to contribute 38% of all IT & ITES revenue by Financial Year 2025. Indian IT industry employed 4.1 Million people with a budget of about \$90 Billion in Financial Year 2019. Due to lowering of IT systems related spend by most customers (except infrastructure spend, which will grow to accommodate remote work and business support), the hiring trend could dip in Financial Year 2021.

The Indian economy witnessed a cyclical slowdown in Financial Year 2020. The COVID-19 outbreak compelled the government to impose a nationwide lockdown in the last week of March which brought economic activities to a halt. The IMF estimates India to grow at 1.9% in Financial Year 2021, before rebounding sharply by 7.4% in Financial Year 2021. The central government announced a massive ₹ 20 Trillion stimulus in tranches to minimize the impact, including an ₹ 1.7 Trillion package directed

at daily wage earners and the bottom of the pyramid. The IMF lauded India’s efforts in using digital technologies to directly deliver the benefits to its citizens.

2. OPPORTUNITIES:

The Company have been on the digital journey from the date since incorporation. At the beginning of the new decade, significant business value will come from greater enterprise composability—enabled by a digital mosaic of business solutions, applications, data platforms and infrastructure, constrained software standards and outdated architectures, businesses have the potential to create a unique digital mosaic for their organization. This new architecture unlocks increased flexibility, operational speed and the freedom to pursue opportunities and growth well outside legacy value chains. In this environment Business and IT leaders can more effectively partner to create business value from technology investments at a much faster pace and at scale. Businesses need innovative and customized solutions that offer intuitive and frictionless digital experiences with a seamless customer journey.

3. FINANCIAL CONDITION AND OPERATIONAL PERFORMANCE:

a. Share Capital

The Company has at present only one class of shares. The Authorized Share Capital is 15,00,00,000 Equity shares of ₹ 1 each, constituting to ₹ 15,00,00,000. There was no increase in the issued, subscribed and paid up capital of the Company during the year under review.

b. Shareholder Funds

The total shareholder funds were ₹ 2,38,33,239 as at 31st March, 2020 against ₹ 2,36,99,405 as of the previous year end, an increase of 0.56% YoY.

c. Profit & Loss account

The Profit after tax (PAT) for the year ended 31st March 2020 is ₹ 1,33,832.

d. Fixed Assets

During the Financial Year 2019-2020 there was no addition in the asset of the Company.

e. Net Worth

The return on Net worth (RONW) for the year ended 31st March, 2020 is 0.56%.

f. Income

The revenue from operations for the year ended 31st March, 2020, of ₹ 9,87,500 and ₹ 10,20,000 were derived from IT Services and Software Sales, respectively.

g. Earnings before Interest, Depreciation and Tax (EBIDTA)

The Company achieved Earnings before Interest, Depreciation and Tax (EBIDTA) of ₹ 1,48,277 against ₹ 3,17,408 as of the previous year ended.

h. Earnings per share (EPS)

Earnings per share (EPS) for the year ended 31st March, 2020 is ₹ 0.003 and previous year ended 31st March, 2019 is ₹ 0.005.

4. SEGMENT WISE / PRODUCT WISE PERFORMANCE:

As the Company is operating in single segment, product wise disclosure of performance is not required to be made.

5. RISKS, CONCERNS AND THREATS:

Risk is an inherent part of any business. There are various types of risks that threaten the existence of a Company like Strategic Risk, Technology Risk, Political Risk, Business Risk, Finance Risk, Foreign Exchange Risk, Environment Risk, Personnel Risk, Operational Risk, Reputation Risk, Regulatory Risk, Geography Risk, Competition Risk etc. Your Company aims at enhancing and maximizing shareholders value by achieving appropriate trade-off between risk & return.

We are exposed to the business risk due to the global outbreak of COVID-19 pandemic. This has resulted in an unprecedented global health crisis, economic crisis, logistics and supply chain disruptions, governmental restrictions, lock-downs and new compliance requirements and international geo-political and trade tensions. The Company will continue to monitor the situation and business outlook, while closely watching our cash position and expenses and respond appropriately with corrective actions.

6. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

Your company has an Internal Control System, commensurate with the size, scale and complexity of its operations. To maintain its objectivity and independence, the Internal Auditor reports to the Chairman of the Audit Committee of the Board. The internal auditor monitors and evaluates the efficacy and adequacy of the internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company. The audit firm periodically evaluates and tests the efficacy and adequacy of internal controls. The internal control systems also aim to strengthen the overall assurance practices, processes and controls. Significant audit observations and

follow up actions thereon are reported to the Audit Committee. The Internal Control systems are designed to provide assurances on an ongoing basis so that the business operations function efficiently and ensure that applicable laws, rules, regulations and policies of the Company are followed and there liability of financial reporting is safeguarded.

The Statutory Auditors of the Company have audited the financial statements forming part of this Annual Report and have issued an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

7. BUSINESS OUTLOOK:

Leading Analysts research reports indicate that the investments in Global Engineering R&D and Digital transformation is set to grow to approximately US\$660 billion by 2023. While the traditional R&D will see a flat trend, the newer investments are bound to see a huge jump in the coming years. Hence, your company's strategy to stay invested in the new age digital technologies will be the top priority. This would give more stability of currency, equity and other dominant factors. The Management of the Company is looking for a steady growth of the Company and aims at maximizing the shareholders wealth by way of earning maximum profits at low investment costs.

8. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS:

The Company would like to place on record, sincere appreciation for the valuable contribution and support of all its employees towards the performance and growth of the Company. Your Company is happy to have a management team comprising of professionals with a proven track record. There have been no material developments in Human Resources during the Financial Year 2019-2020. The Company continues to remain focused and sensitive to the role of human resources in optimizing results in all its areas of working and its industrial relations also continue to be cordial.

9. DETAILS OF SIGNIFICANT CHANGES (I.E. CHANGE OF 25% OR MORE AS COMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR) IN KEY FINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREFOR:

There are no significant changes of 25% or more in key financial ratios as compared to the previous Financial Year.

ANNEXURE-E TO DIRECTORS' REPORT**Form No. AOC-2****[Pursuant to clause (h) of sub-section (3) of Section 134 of the Companies Act, 2013
and Rule 8(2) of the Companies(Accounts) Rules, 2014]**

Form for disclosure of particulars of contracts / arrangements entered into by the Company with the related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arms-length transactions under third proviso thereto

1. Details of contracts or arrangements or transactions not at arm's length basis – NA

- a) Name(s) of the related party and nature of relationship : **NA**
- b) Nature of contracts/arrangements/transactions : **NA**
- c) Duration of the contracts / arrangements/ transactions : **NA**
- d) Salient terms of the contracts or arrangements or transactions including the value, if any : **NA**
- e) Justification for entering into such contracts or arrangements or transactions : **NA**
- f) Date(s) of approval by the Board : **NA**
- g) Amount paid as advances, if any : **NA**
- h) Date on which the special resolution was passed in general meeting as required under first proviso to Section 188 : **NA**

2. Details of material contracts or arrangement or transactions at arm's length basis – NIL

- a) Name(s) of the related party and nature of relationship : **NIL**
- b) Nature of contracts / arrangements / transactions : **NIL**
- c) Duration of the contracts / arrangements / transactions : **NIL**
- d) Salient terms of the contracts or arrangements or transactions including the value, if any : **NIL**
- e) Date(s) of approval by the Board, if any : **NIL**
- f) Amount paid as advances, if any : **NIL**

Notes:

- 1. As defined under Regulation 23 of the Listing Regulations and the Policy on Related Party Transactions adopted by the Board of Directors of the Company, there were no **Material** Related Party Transaction entered during the Financial Year 2019-2020.
- 2. All transactions with related parties were in the Ordinary Course of Business and at arm's length basis and were approved by the Audit Committee and the Board of Directors of the Company.

**On behalf of Board of Directors
For, Kashyap Tele-Medicines Limited**

Sd/-

**Amit Agrawal
Managing Director
DIN: 00169061**

Date : 7th August, 2020**Place: Ahmedabad**

MANAGING DIRECTOR (MD) AND CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

To,
The Board of Directors,
Kashyap Tele-Medicines Limited

In pursuance to Regulation 17(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We, Amit Agrawal, Managing Director (MD) and Raghav Agrawal, Chief Financial Officer (CFO) of the Company, hereby certify that:

- A. We have reviewed financial statements and the cash flow statement for the year ended 31st March, 2020 and that to the best of their knowledge and belief:
- 1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - 2) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of their knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that they have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and they have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which they are aware and the steps they have taken or propose to take to rectify these deficiencies.
- D. We further certify that we have indicated to the auditors and the Audit committee:
- 1) there have been no significant changes in internal control over financial reporting during the year;
 - 2) there have been no significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - 3) there have been no instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

Date : 26th June, 2020
Place : Ahmedabad

Sd/-
Amit Agrawal
Managing Director
DIN: 00169061

Sd/-
Raghav Agrawal
Chief Financial Officer/Director
DIN: 02264149

INDEPENDENT AUDITOR'S REPORT

To,
The Members
Kashyap Tele Medicines Limited
Mumbai

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **Kashyap Tele Medicines Limited** which comprises the Balance Sheet as at 31st March, 2020, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS") and accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2020, and the profit, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibility for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant for audit of financial statement under the provisions of the Act and the Rules made thereunder and we have fulfilled our ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters :

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements of the current year. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matter	Auditor's Response
<p>Assessment of carrying value of equity investments and fair value of other investments</p> <p>The Company has equity investments in other companies. The accounting for investments is a Key Audit Matter as the determination of recoverable value for impairment assessment/fair valuation involves significant management judgement.</p> <p>The Company accounts for equity investments at cost (subject to impairment assessment)</p>	<p>Our audit procedures included the following:</p> <ul style="list-style-type: none"> We obtained an understanding from the management, assessed and tested the design and operating effectiveness of the Company's key controls over the impairment assessment and fair valuation of material investments. We assessed the carrying value/fair value calculations of all individually material investments, where applicable, to determine whether the valuations performed by the Company were within an acceptable range determined by us and the auditor's valuation experts. We evaluated the cash flow forecasts (with underlying economic growth rate) by comparing them to the approved budgets and our understanding of the internal and external factors. We had discussions with management to obtain an understanding of the relevant factors in respect of certain investments carried at fair value where a wide range of fair values were possible due to various factors such as absence of recent observable transactions, restrictions on transfer of shares, existence of multiple valuation techniques, investee's varied nature of portfolio of investments for which significant estimates/judgements are required to arrive at fair value. We evaluated the adequacy of the disclosures made in the Standalone Financial Statements. <p>Based on the above procedures performed, we did not identify any significant exceptions in the management's assessment in relation to the carrying value of equity investments.</p>

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Cash Flow dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on 31st March, 2020 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any impact of pending litigations on its financial position in its financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
2. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Companies Act, 2013, we give in the "Annexure-B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

For, SAREMAL & Co.
Chartered Accountants
Firm Registration No. 109281W

PRAVIN LAVANA
Partner

Place : Ahmedabad
Date : 26th June 2020

Membership No.037180
UDIN: 20037180AAAABD3206

Annexure -A to the Independent Auditors' Report

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our Report of even date)

Report on the Internal Financial Controls over financial reporting under Clause (i) of sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Kashyap Tele Medicines Limited** as on 31st March, 2020 in conjunction with our audit of financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing, prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal financial control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For, SAREMAL & Co.
Chartered Accountants
Firm Registration No. 109281W

PRAVIN LAVANA
Partner

Place : Ahmedabad
Date : 26th June 2020

Membership No.037180
UDIN: 20037180AAAABD3206

Annexure -B to the Independent Auditors' Report

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our Report of even date)

As explained to us, the Company do not have any inventory during the respective financial year.

(i) In respect of Fixed Assets which have been derecognized pursuant to Appendix-C of Ind AS-115 and recognized as financial assets:

(a) The Company does not have any fixed assets during the financial year.

(ii) As explained to us, the Company do not have any inventory during the respective financial year.

(iii) According to information and explanation given to us, the Company has not granted loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Companies Act, 2013 therefore the provision of Clause 3(iii) of the Order is not applicable to the Company.

(iv) In our opinion and according to information and explanations given to us, the Company has not made any loan, guarantees or security and therefore the provision of Clause 3(iii) of the Order is not applicable to the Company.

(v) According to information and explanation given to us, the Company has not accepted any deposits as defined in The Companies (Acceptance of Deposits) Rules 2014. Accordingly, the provision of Clause 3(v) of the order is not applicable to the Company.

(vi) The Central Government has not prescribed maintenance of cost records under sub-section(1) of Section 148 of the Companies Act, 2013, for the business activities carried out by the Company and therefore, reporting under Clause 3(vi) of the Order is not applicable to the Company

(vii) According to the information and explanations given to us, in respect of statutory dues:

(a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues applicable to it with the appropriate authorities.

(b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues in arrears as at 31st March, 2020 for a period of more than six months from the date they became payable.

(viii) In our opinion and according to information and explanations given to us, the Company has not defaulted in the repayment

of loans and borrowings to financial institutions, banks, government or dues to debenture holders during the year.

(ix) In our opinion and according to information and explanations given to us, the Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, paragraph 3 (ix) of the Order is not applicable.

(x) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company and no material fraud on the Company by its officers or employees has been noticed or reported during the course of our audit.

(xi) In our opinion and according to the information and explanations give to us and based on our examination of the records of the Company, the Company has not provided any managerial remuneration. Accordingly reporting under clause 3(xi) of the Order is not applicable to the Company.

(xii) In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly reporting under clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the Company is in compliance with Sections 177 and 188 of the Companies Act, 2013 where applicable for all transactions with related parties and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv) During the year the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures and therefore, the reporting under clause 3 (xiv) of the Order is not applicable to the Company.

(xv) In our opinion and according to the information and explanations given to us, during the year the Company has not entered into non-cash transactions with directors or persons connected with him and hence provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) The Company as legally advised, is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Therefore, the reporting under clause (xvi) of the Order is not applicable to the Company.

For, SAREMAL & Co.
Chartered Accountants
Firm Registration No. 109281W

PRAVIN LAVANA
Partner

Membership No.037180

UDIN: 20037180AAAABD3206

Place : Ahmedabad
Date : 26th June 2020

Balance Sheet as at 31st March, 2020

CIN : L29110MH1995PLC085738

(Amount in ₹)

Particulars	Notes No.	As at 31 st March, 2020	As at 31 st March, 2019
Assets			
Non-current assets			
Financial assets			
- Investments	5	2,100,000	2,100,000
- Other financial assets	6	34,052	34,052
Other non-current assets	7	19,169,184	19,169,184
Total non-current assets		21,303,236	21,303,236
Current assets			
Financial assets			
- Trade receivables	8	1,298,653	1,239,852
- Cash and cash equivalents	9	1,077,287	1,462,162
- Loans	10	-	-
Other current assets	11	284,778	74,630
Total current assets		2,660,718	2,776,644
Total assets		23,963,955	24,079,880
Equity and liabilities			
Equity			
Equity share capital	12	47,722,000	47,722,000
Other equity	13	(23,888,761)	(24,022,595)
Total equity		23,833,239	23,699,405
Liabilities			
Current liabilities			
Financial liabilities			
- Trade payables	14	-	29,912
- Other financial liabilities	15	97,206	270,241
Other current liabilities	16	-	-
Current-tax liabilities	17	33,510	80,322
Total current liabilities		130,716	380,475
Total equity and liabilities		23,963,955	24,079,880

The accompanying notes form an integral part of these financial statements

As per our report of even date

For, Saremal & Co.
Chartered Accountants

Pravin Lavana
(Partner)
Firm Registration No.: 109281W
Membership No. 037180

Place: Ahmedabad
Date : 26th June, 2020

For and on behalf of Board of Directors of
Kashyap Tele-Medicines Limited

Managing Director
(Mr. Amit Y Agrawal)
(DIN :00169061)

Company Secretary
(CS Prerna Kakkar)

Director
(Mrs. Amrita Khetan)
(DIN :02781781)

CFO/Director
(Mr. Raghav Agrawal)
(DIN :02264149)

Statement of Profit and Loss for the year ended 31st March, 2020

CIN : L29110MH1995PLC085738

(Amount in ₹)

Particulars	Notes No.	Year ended 31 st March, 2020	Year ended 31 st March, 2019
Income			
Revenue from operations	18	2,007,500	1,985,000
Other income	19	-	-
Total income		2,007,500	1,985,000
Expenses			
Employee benefits expense	20	908,384	993,320
Other expenses	21	952,657	682,746
Total expenses		1,861,041	1,676,066
Profit/(loss) before exceptional items and tax		146,459	308,934
Exceptional items		-	-
Profit before tax		146,459	308,934
Tax expense:			
Current tax	22	33,510	78,162
Tax relating to previous year		-20,883	-
Income tax expense	23	12,627	78,162
Profit for the year		133,832	230,772
Other comprehensive income			
Items not to be reclassified to profit or loss in subsequent periods			
Re-measurement gains/ (losses) on defined benefit plans			-
Foreign exchange (loss)			-
Income tax related to item that will not be reclassified to profit and loss	(b)		-
Net other comprehensive (expense) not to be reclassified to profit or loss in subsequent periods			-
Total comprehensive income for the year		133,832	230,772
Earnings per equity share			
Basic and diluted earnings per equity shares	24	0.003	0.005

The accompanying notes form an integral part of these financials statements

As per our report of even date

For, Saremal & Co.
Chartered Accountants

Pravin Lavana
(Partner)
Firm Registration No.: 109281W
Membership No. 037180

Place: Ahmedabad
Date : 26th June, 2020

For and on behalf of Board of Directors of
Kashyap Tele-Medicines Limited

Managing Director
(Mr. Amit Y Agrawal)
(DIN :00169061)

Company Secretary
(CS Prerna Kakkar)

Director
(Mrs. Amrita Khetan)
(DIN :02781781)

CFO/Director
(Mr. Raghav Agrawal)
(DIN :02264149)

Cash flow statement for the year ended 31st March, 2020

CIN : L29110MH1995PLC085738

(Amount in ₹)

Particulars	Year ended 31 st March, 2020	Year ended 31 st March, 2019
A Cash flow from operating activities:		
Profit before tax	146,459	308,934
Adjustments		
Operating profit before working capital changes	146,459	308,934
Adjustments for changes in working capital :		
Change in trade receivables	(58,801)	(15,000)
Change in other receivables	(210,148)	(37,400)
Change in Current Liabilities & other payables	(202,947)	154,969
Cash flow from/ (used in) operations	(325,437)	411,503
Income taxes paid	59,440	91,796
Net cash flow from/(used in) operating activities	(384,877)	319,707
B Cash flow from investing activities:		
Net cash (used in)/flow from investing activities	-	-
C Cash flow from financing activities:		
Net cash (used in)/flow from financing activities:	-	-
D Net increase in cash and cash equivalents	(384,877)	319,707
Cash and cash equivalents at the beginning of the year (refer note 19)	1,462,162	1,142,455
Cash and cash equivalents at the end of the year	1,077,287	1,462,162
E Cash and cash equivalents comprises of:		
Balances with banks		
on current accounts	1,045,287	1,457,762
Cash on hand	32,000	4,400
	1,077,287	1,462,162

The accompanying notes form an integral part of these financials statements.

As per our report of even date

For, Saremal & Co.
Chartered Accountants

Pravin Lavana
(Partner)
Firm Registration No.: 109281W
Membership No. 037180

Place: Ahmedabad
Date : 26th June, 2020

For and on behalf of Board of Directors of
Kashyap Tele-Medicines Limited

Managing Director
(Mr. Amit Y Agrawal)
(DIN :00169061)

Company Secretary
(CS Prerna Kakkar)

Director
(Mrs. Amrita Khetan)
(DIN :02781781)

CFO/Director
(Mr. Raghav Agrawal)
(DIN :02264149)

Statement of Changes in Equity for the year ended 31st March, 2020

CIN : L29110MH1995PLC085738

A. Equity share capital (Note 12)

(Amount in ₹)

	Number of shares	As at 31 st March, 2020	As at 31 st March, 2019
Authorized Share Capital (Equity shares of ₹ 1/- each)	150,000,000	150,000,000	150,000,000
Issued Share Capital (Equity shares of ₹ 1/- each)	50,000,000	50,000,000	50,000,000
Subscribed and Paid up Share Capital (Equity shares of ₹ 1/- each)	47,722,000	47,722,000	47,722,000
Total	47,722,000	47,722,000	47,722,000

Equity shares of ₹ 1/- each subscribed and fully paid up	Number of shares	Amount
As at 31st March 2019	47,722,000	47,722,000
Issue/reduction, if any during the year	-	-
As at 31st March 2020	47,722,000	47,722,000

B. Other equity (Note 13)

(Amount in ₹)

Particulars	Retained earnings	Total
As on 31st March, 2018	(25,450,867)	(25,450,867)
Profit for the year	230,772	230,772
Movement for the year	-	-
As on 31st March, 2019	(25,220,095)	(25,220,095)
Capital Reserve	1,197,500	1,197,500
As on 31st March, 2019	(24,022,595)	(24,022,595)
Profit for the year	133,832	133,832
Movement for the year	-	-
As on 31st March, 2020	(23,888,761)	(23,888,761)

The accompanying notes form an integral part of these financials statements.

As per our report of even date

For, Saremal & Co.
Chartered Accountants

Pravin Lavana
(Partner)
Firm Registration No.: 109281W
Membership No. 037180

Place: Ahmedabad
Date : 26th June, 2020

For and on behalf of Board of Directors of
Kashyap Tele-Medicines Limited

Managing Director
(Mr. Amit Y Agrawal)
(DIN :00169061)

Company Secretary
(CS Prerna Kakkar)

Director
(Mrs. Amrita Khetan)
(DIN :02781781)

CFO/Director
(Mr. Raghav Agrawal)
(DIN :02264149)

Notes to standalone financials statements for the year ended 31st March, 2020

1 Corporate information

Kashyap Tele-Medicines Limited ('the Company') is a public Company, domiciled in India under the provision of the Companies Act, 2013. The Company is engaged in Software sales and its maintenance and services.

2 Basis of preparation

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.

The financial statements have been prepared on the historical cost basis, except for certain financial instruments which are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

The financial statements are presented in Indian rupees (INR) and all values are presented in full, except otherwise indicated.

3 Summary of significant accounting policies

3.1 Current vs Non Current Classification

The Company presents assets and liabilities in the Balance Sheet base on current/non-current classification.

An asset is current when it is:

- i) Expected to be realised or intended to be sold or consumed in normal operating cycle
- ii) Held primarily for the purpose of trading
- iii) Expected to be realised within twelve months after the reporting period, or
- iv) Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current

A liability is current when it is:

- i) Expected to be settled in normal operating cycle
- ii) Held primarily for the purpose of trading
- iii) Due to be settled within twelve months after the reporting period, or
- iv) There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are treated as non-current

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

3.2 Revenue recognition

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

"IND AS 115 establishes a comprehensive framework for determining whether, how much and when revenue is recognised. It replaced IND AS 18 Revenue, IND AS 11 Construction Contracts and related interpretations. Under IND AS 115, revenue is recognised when a customer obtains control of the goods or services. Revenue is recognised to the extent that it is probable that the Company will collect the consideration to which it is entitled. Determining the timing of the transfer of control – at a point in time or over time – requires judgement. The Company has adopted IND AS 115 using the cumulative effect method (without practical expedients), with the effect of initially applying this standard recognised at the date of initial application (i.e. 1st April, 2018). Accordingly, the information presented for 31st March, 2018 has not been restated. The Company's current practices for recognising revenue have shown to comply in all material aspects with the concepts and principles encompassed by the new standard including its Appendix. Therefore, IND AS 115 did not have a significant impact on the Company's accounting for revenue recognition."

Interest income

Interest income is recognised using effective interest method (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross amount of the financial asset or to the amortised cost of a financial liability. When calculating the EIR, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument but doesn't consider the expected credit losses. Interest income is included in the other income in the Statement of Profit and Loss.

Dividend income

Dividend income from investments is recognised when the shareholder's rights to receive payment have been established.

3.3 Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

Notes to standalone financial statements for the year ended 31st March, 2020

3.4 Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

3.5 Taxes

The tax expense for the period comprises current and deferred tax. Tax is recognised in the Statement of Profit and Loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

Current income tax

Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the taxation laws prevailing and applicable for the relevant assessment year. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax

Deferred income taxes are recognised for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases in the financial statements. The effect on deferred tax assets and liabilities of a change in the tax rates is recognised using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred tax liabilities relate to the same taxable entity and the same taxation authority.

Tax Reconciliations

The Company has elected to exercise the option of a lower tax rate provided under Section 115BAA of the Income-tax Act, 1961, as introduced by the Taxation Laws (Amendment) Ordinance, 2019 dated 20th September, 2019. Accordingly, the Company has recognised provision for income tax for the year

ended and remeasured its deferred tax assets basis the rate provided in the said section.

(i) 'Amendment to Ind AS 12 – Income taxes

'The amendment relating to income tax consequences of dividend clarify that an entity shall recognise the income tax consequences of dividends in profit or loss, other comprehensive income or equity according to where the entity originally recognised those past transactions or events. The adoption of the standard did not have any material impact to the financial statements. It is relevant to note that the amendment does not amend situations where the entity pays a tax on dividend which is effectively a portion of dividends paid to taxation authorities on behalf of shareholders. Such amount paid or payable to taxation authorities continues to be charged to equity as part of dividend in accordance with Ind AS 12.

In the situations where the Company is entitled to a tax holiday under the Income-tax Act, 1961, no deferred tax (asset or liability) is recognised in respect of temporary differences which reverse during the tax holiday period, to the extent the Company's gross total income is subject to the deduction during the tax holiday period. Deferred tax in respect of temporary differences which reverse after the tax holiday period is recognised in the year in which the temporary differences originate. However, the Company restricts recognition of deferred tax assets to the extent that it has become reasonably certain, that sufficient future taxable income will be available against which such deferred tax assets can be realized. For recognition of deferred taxes, the temporary differences which originate first are considered to reverse first.

3.6 Impairment of non-financial assets

At each balance sheet date, the Company reviews the carrying values of its property, plant and equipment and intangible assets to determine whether there is any indication that the carrying value of those assets may not be recoverable through continuing use. If any such indication exists, the recoverable amount of the asset is reviewed in order to determine the extent of impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. An impairment loss is recognised in the statement of profit and loss as and when the carrying value of an asset exceeds its recoverable amount.

Notes to standalone financials statements for the year ended 31st March, 2020

Where an impairment loss subsequently reverses, the carrying value of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount so that the increased carrying value does not exceed the carrying value that would have been determined had no impairment loss been recognised for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognised in the statement of profit and loss immediately

3.7 Provisions, contingent liabilities, contingent assets and commitments

A provision is recognised when there is a present legal or constructive obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, and in respect of which a reliable estimate can be made. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. A disclosure for a contingent liability is made where there is a possible obligation arising out of past event, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation arising out of past event where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

3.8 Fair value disclosures for financial assets and financial liabilities

The management believes that the fair values of non-current financial assets (e.g. Investments at FVPL, loans and others), current financial assets (e.g. cash equivalents, trade and other receivables, loans), non-current financial liabilities and current financial liabilities (e.g Trade payables and other payables and others) approximate their carrying amounts. The Company has not performed a fair valuation of its investment in unquoted equity shares other than subsidiary, which are classified as FVOCI (refer Note 4), as the Company believes that impact of change on account of fair value is insignificant. Fair value of quoted investment in mutual fund is determined by reference to available net asset value (NAV) available from respective Assets Management Companies ("AMC").

3.9 Fair value measurement

The Company measures financial instruments, such as, investments and derivatives, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- > In the principal market for the asset or liability, or
- > In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- > Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- > Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- > Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company's Management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted/quoted financial assets measured at fair value.

Notes to standalone financial statements for the year ended 31st March, 2020

External valuers are involved for valuation of unquoted financial assets and financial liabilities. Involvement of external valuers is decided upon annually by the Management. Selection criteria includes market knowledge, reputation, independence and whether professional standards are maintained. The Management decides, after discussions with The Company's external valuers, which valuation techniques and inputs to use for each case.

At each reporting date, the Company analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Company's accounting policies. For this analysis, the Company verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents.

The Company, in conjunction with the Company's external valuers, also compares the change in the fair value of each asset and liability with relevant external sources to determine whether the change is reasonable on a yearly basis.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

3.10 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in following categories:

A) Equity instruments

All equity instruments are subsequently measured at fair value in the balance sheet, with value changes recognised in statement of profit and loss, except for those equity instruments for which the Company has elected to present value changes in "other comprehensive income". If an equity instrument is not held for trading, the Company may make an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in other comprehensive income. The Company makes such election on an instrument by instrument basis.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity.

The Company has elected to present all equity instruments, other than those in subsidiary, through FVTPL and all subsequent changes are recognized in Statement of Profit and Loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- > The rights to receive cash flows from the asset have expired, or
- > The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of financial assets

The Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure;

- a) Financial assets that are debt instruments, and are measured at amortised cost e.g. loans, debt securities, deposits, trade receivables and bank balances

Notes to standalone financials statements for the year ended 31st March, 2020

- b) Financial assets that are debt instruments and are measured as at other comprehensive income (FVTOCI)
- c) Lease receivables under Ind AS 17
- d) Trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 11 and Ind AS 18

The Company follows 'simplified approach' for recognition of impairment loss allowance on:

- > Trade receivables or contract revenue receivables; and
- > All lease receivables resulting from transactions within the scope of Ind AS 17

Under the simplified approach the Company does not track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk said initial recognition. If credit risk has not increased significantly, 12 month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period the credit risk reduces since initial recognition, then the entity reverts to recognizing impairment loss allowance based on 12 month ECL.

As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward looking estimates are analysed. The Company has presumed that default doesn't occur later than when a financial asset is 90 days past due.

ECL is the difference between all contracted cash flows that are due to the Company in accordance with the contract and all the cash flows that the Company expects to receive, discounted at the original EIR. ECL impairment loss allowance (or reversal) recognised during the period is recognised as income / (expense) in the statement of profit and loss (P&L). This amount is reflected under the head "Other Expense" in the P&L. The impairment loss is presented as an allowance in the Balance Sheet as a reduction from the net carrying amount of the trade receivable, loan, deposits and lease receivable respectively.

Financial liabilities

Initial recognition and measurement

All financial liabilities are initially recognised at fair value. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdraft and derivative financial instruments.

Subsequent measurement

Subsequent measurement of financial liabilities depends on their classification as fair value through Profit and loss or at amortized cost.

All changes in fair value of financial liabilities classified as FVTPL is recognized in the Statement of Profit and Loss. Amortised cost category is applicable to loans and borrowings, trade and other payables. After initial recognition the financial liabilities are measured at amortised cost using the EIR method. Gains and losses are recognized in profit and loss when the liabilities are derecognized as well as through the EIR amortization process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or cost that are integral part of the EIR. The EIR amortization is included as finance cost in the Statement of Profit and Loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Derivative financial instruments

The Company uses derivative financial instruments, such as forward currency contracts to hedge its foreign currency risks. Such derivative financial instruments are initially recognised at fair value through profit or loss (FVTPL) on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

Any gains or losses arising from changes in the fair value of derivative financial instrument are recognised in the statement of profit and loss.

Reclassification of financial instruments

After initial recognition, no reclassification is made for financial assets which are equity instruments. For financial assets, which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. If the Company reclassifies the financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in the business model.

Offsetting financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable

Notes to standalone financials statements for the year ended 31st March, 2020

legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

4 Significant accounting estimates and assumptions

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

Impairment of non-financial assets

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a discounted cash flow model. The cash flows are derived from the budget for the next five years and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the asset's performance being tested. The recoverable amount is sensitive to the discount rate used for the discounted cash flow model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes.

Taxes

Deferred tax assets are recognised for unused tax credits to the extent that it is probable that taxable profit will be available against which the credits can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgment is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments."

4.1 Other Disclosures:

Standards issued but not effective

As at the date of issue of financial statements, there are no new standards or amendments which have been notified by the MCA but not yet adopted by the Company. Hence, the disclosure is not applicable.

Events Occurring After Balance - Sheet

The Company evaluates events and transactions that occur subsequent to the balance sheet date but prior to the approval of financial statements to determine the necessity for recognition and/or reporting of any of these events and transactions in the financial statements. As of 31st March, 2020, there were no subsequent events to be recognised or reported that are not already disclosed.

Impact of Covid – 19

In the last week of March 2020, an outbreak situation arose in India on account of COVID-2019. The Company has considered such outbreak situation as subsequent event to the Balance Sheet date i.e., 31st March, 2020 in terms of Ind AS 10 "Reporting on Event After Balance Sheet Date" and has assessed the operational and financial risk on going forward basis though Company's operations continued in the given situation.

In assessing the impact on the recoverability of financial and non-financial assets, the Company has considered internal and external information up to the date of approval of these financial statements including credit reports and economic forecasts whereby it expects to recover the carrying amounts of the assets. The Company has performed sensitivity analysis on the assumptions used on assessing the impact on the Company's operations. On overall basis, the management does not see any medium to long term risks in the Company's ability to continue as a going concern and meeting its liabilities as and when they fall due, and compliance with the debt covenants, as applicable.

The impact on the operations and earnings/ cashflows of the Company due to COVID- 2019 outbreak may be different from that estimated as at date of approval of these financial statements and the Company will continue to closely monitor any material changes to future economic conditions.

Notes to standalone financials statements for the year ended 31st March, 2020

5 Investments (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Non current investments		
Unquoted equity instruments - at cost		
Investment in equity shares		
(a) Investment in equity shares- fully paid up		
KHANDELWAL INFRASTRUCTURE PRIVATE LIMITED (50000 Shares of ₹ 20/- each)	1,000,000	1,000,000
MELWINO INDUSTRIES LIMITED (55000 Shares of ₹ 20/- each)	1,100,000	1,100,000
	2,100,000	2,100,000
Aggregate amount of unquoted investments	2,100,000	2,100,000

6 Other financial assets (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Telephone deposit	34,052	34,052
	34,052	34,052

7 Other non-current assets (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Long term advances	19,169,184	19,169,184
	19,169,184	19,169,184

8 Trade receivables (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
(Unsecured, considered good unless otherwise stated)		
Trade receivables		
from others	1,298,653	1,239,852
	1,298,653	1,239,852

8.1 Trade receivables are measured at amortised cost.

9 Cash and cash equivalents (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Balances with banks:		
Balance in current account	1,045,287	1,457,762
Cash on hand	32,000	4,400
	1,077,287	1,462,162

Notes to standalone financials statements for the year ended 31st March, 2020

10 Loans (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
(Unsecured, considered good unless otherwise stated)	-	-
Loans and advances to employees	-	-

11 Other current assets (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Pre- Paid Exp.	5,648	-
Balances with statutory authorities	279,130	74,630
	284,778	74,630

12 Share capital (Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Authorised Share Capital (Equity Shares of ₹1 each)	150,000,000	150,000,000
Issued Share Capital (Equity Shares of ₹1 each)	50,000,000	50,000,000
Subscribed and Paid up Share Capital (Equity Shares of ₹1 each)	47,722,000	47,722,000
Total	47,722,000	47,722,000

Notes:

(a) Reconciliation of the number of the shares outstanding as the beginning and end of the year: (Amount in ₹)

Particulars	As at 31 st March, 2020		As at 31 st March, 2019	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the year	47,722,000	47,722,000	47,722,000	47,722,000
Movement during the year	-	-	-	-
At the end of the year	47,722,000	47,722,000	47,722,000	47,722,000

(b) Terms/rights attached to equity shares:

The Company has only one class of equity shares having a par value of ₹1 per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders.

The Company did not declare any dividend on equity shares for the year ended 31st March, 2020 and 31st March, 2019. The dividend if proposed by the Board of Directors, is subject to the approval of shareholders in the Annual General Meeting, except interim dividend.

(c) Details of shareholder holding more than 5% shares in the Company

Equity shares of ₹ 1 each fully paid		As at 31 st March, 2020	As at 31 st March, 2019
Jindal Worldwide Limited	Number of Shares	14,915,000	14,915,000
	% Holding	31.25%	31.25%
Amitara Industries Private Limited	Number of Shares	12,380,751	12,380,751
	% Holding	25.94%	25.94%

Notes to standalone financials statements for the year ended 31st March, 2020

(d) Shares reserved for issue under option

The Company has not reserved any shares for issuance under options

(e) Aggregate number of bonus shares issued, share issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting date

The Company has neither issued any bonus shares, shares for consideration other than cash nor has there been any buyback of shares in the current year and preceding five years from 31st March 2020.

13 Other equity

(Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
(i) Retained earnings		
Opening balance	(25,220,095)	(25,450,867)
Add: Profits for the year	133,832	230,772
Closing balance	(25,086,261)	(25,220,095)
(ii) Security premium	-	-
(iii) Capital Reserve	1,197,500	1,197,500
Total	(23,888,761)	(24,022,595)

14 Trade payables

(Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Total outstanding due to micro enterprises and small enterprises	-	-
Total outstanding due of creditors other than micro enterprises and small enterprises	-	29,912
Total	-	29,912

15 Other financial liabilities

(Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Other current financial liabilities		
Others	97,206	270,241
Total	97,206	270,241

16 Other current liabilities

(Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Statutory dues	-	-
Total	-	-

17 Income-tax liabilities

(Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019
Income tax provision	33,510	80,322
Total	33,510	80,322

Notes to standalone financial statements for the year ended 31st March, 2020

18 Revenue from operations

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
Sale of products and services		
Income from projects and services	987,500	840,000
Software sales	1,020,000	1,145,000
	2,007,500	1,985,000

19 Other income

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
Dividend	-	-
	-	-

20 Employee benefits expense

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
Salaries, wages and allowance	908,384	993,320
	908,384	993,320

21 Other expenses

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
Repairs & Maintenance	-	15,859
Lease Rent	10,000	-
Share registry & maintenance charges	89,608	93,478
Bank charges	1,886	380
Listing expenses	354,000	295,000
Postage and courier	2,766	2,914
Professional fees	139,618	48,608
Excess Income Tax Provision	-	-
Sundry balances written off	133,709	-
Interest on income tax	1,818	8,474
Issuer fees	29,322	28,607
Filing fees	9,900	7,300
Auditor remuneration	29,500	34,000
Telephone Exp.	3,354	2,904
Travelling expenses	34,290	55,000
Membership fees	17,700	
Printing & stationary	25,830	23,100
Advertisement	69,356	67,122
	952,657	682,746
* Payment to auditor		
As auditor:		
Audit fee	29,500	29,500
	29,500	29,500

Notes to standalone financials statements for the year ended 31st March, 2020

22 Income tax profit and loss section

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
(a) Income tax recognised in statement of profit and loss:		
Current income tax	12,627	78,162
Income tax expenses reported in statement of profit and loss	12,627	78,162
(b) Income tax recognised in other comprehensive income		
Current Income tax		
Net gain/(loss) on re-measurement of defined benefit plans	-	-
Classification of income-tax recognized in other comprehensive income		
Income-taxes related to items that will not be reclassified to Profit and Loss	-	-
Income-taxes related to items that will be reclassified to Profit and Loss	-	-

23 The income tax expense can be reconciled to the accounting profit as follows:

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
Accounting profit before tax	146,459	308,934
Income tax rate as per Income Tax Act 1961 (2020 = 22.88% and 2019 = 26%)	33,510	80,323
Adjustment in respect of: Tax relating to Previous Year	(20,883)	(2,161)
Income tax reported in statement of profit and loss	12,627	78,162

24 Earnings per share

Basic EPS amounts are calculated by dividing the profit for the year attributable on equity holders of the company by the weighted average number of equity shares outstanding during the year.

(Amount in ₹)

	For the year ended 31 st March, 2020	For the year ended 31 st March, 2019
The following reflects the income and share data used in the basic & diluted EPS computation		
Basic and diluted earning per share		
Profit attributable to equity shareholders of the Company for basic & diluted earning	133,832	230,772
Weighted average number of equity shares for basic & diluted EPS	47,722,000	47,722,000
Basic and diluted earning per share (in ₹)	0.003	0.005

Notes to standalone financials statements for the year ended 31st March, 2020

25 Capital management

- (a) The Company's capital management objective are to ensure Company's ability to continue as a going concern as well to create value for shareholders by facilitating the meeting of long term and short term goals of the Company. The Company determines the amount of capital required on the basis of annual business plan coupled with long term and short term strategic investment and expansion plans. The funding needs are met through cash generated from operations, long term and short term bank borrowings. The Company monitors the capital structure on the basis of net debt to equity ratio and maturity profile of the overall debt portfolio of the Company. Net debt includes interest bearing borrowings less cash and cash equivalents, other bank balances (including non-current earmarked balances) and current investments. The table below summarises the capital, net debt and net debt to equity ratio of the Company.

(Amount in ₹)			
Particulars	As at 31 st March, 2020	As at 31 st March, 2019	As at 31 st March, 2018
Equity share capital	47,722,000	47,722,000	47,722,000
Other equity	(23,888,761)	(24,022,595)	(24,253,367)
Total equity	23,833,239	23,699,405	23,468,633
Non-current borrowings	-	-	-
Short term borrowings	-	-	-
Current maturities of long term borrowings	-	-	-
Gross Debt	-	-	-
Gross debt as above	-	-	-
Less: Cash and cash equivalents	1,077,287	1,462,162	1,142,455
Net debt	(1,077,287)	(1,462,162)	(1,142,455)
Net debt to equity	(0.045)	(0.062)	(0.049)

26 Fair value measurement

- (a) The carrying value and fair value of financial instruments by categories as of 31st March, 2020 is as follows :

(Amount in ₹)			
Particulars	Fair value through other comprehensive income	Fair value through other profit & loss	Amortised Cost
Financial assets			
Investments	-	-	-
Trade receivables	-	-	1,298,653
Cash and cash equivalents	-	-	1,077,287
Other bank balances	-	-	-
Loans	-	-	-
Others financial assets	-	-	284,778
	-	-	2,660,718
Financial liabilities			
Borrowings	-	-	-
Trade payables	-	-	-
Other financial liabilities	-	-	97,206
	-	-	97,206

Notes to standalone financials statements for the year ended 31st March, 2020

(b) The carrying value and fair value of financial instruments by categories as of 31st March, 2019 is as follows :

(Amount in ₹)

Particulars	Fair value through other comprehensive income	Fair value through other profit & loss	Amortised Cost
Financial assets			
Investments	-	-	-
Trade receivables	-	-	1,239,852
Cash and cash equivalents	-	-	1,462,162
Other bank balances	-	-	-
Loans	-	-	-
Others financial assets	-	-	74,630
	-	-	2,776,644
Financial liabilities			
Borrowings	-	-	-
Trade payables	-	-	29,912
Other financial liabilities	-	-	270,241
	-	-	300,153

The carrying amounts of trade payables and other payables, working capital borrowing current loan and cash & cash equivalents are considered to be the same as fair value, due to short term in nature.

27 The Company is exposed to various risks in relation to financial instruments. The main types of risks are market risk, credit risk and liquidity risk. Company's principal financial liabilities comprises, loans and borrowings, trade and other payables, and financial guarantee contracts. The main purpose of these financial liability is to finance company's operation. Company's principal financial asset include loan to subsidiaries, investments, trade and other receivables, security deposits and cash and cash equivalent, that directly derive from its business.

(a) Credit Risk

Credit Risk in case of the Company arises from cash and cash equivalents, deposits with banks and financial institutions, as well as credit exposures to customers including outstanding receivables.

Credit Risk Management

Credit risk is the risk that a counterparty fails to discharge an obligation to the Company. The Company is exposed to this risk for various financial instruments, for example by granting loans and receivables to customers, placing deposits etc. the Company's maximum exposure to credit risk is limited to the carrying amount of financial assets recognised at 31st March 2020, as summarised below:

(Amount in ₹)

	As at 31 st March, 2020	As at 31 st March, 2019	As at 31 st March, 2018
Loans	-	-	-
Investments	2,100,000	2,100,000	2,100,000
Other financial assets	34,052	34,052	34,052
Cash and cash equivalents	1,077,287	1,462,162	1,142,455
Trade receivables	1,298,653	1,239,852	1,224,853
	4,509,992	4,836,066	4,501,360

The Company continuously monitors defaults of customers and other counterparties and incorporates this information into its credit risk controls. The Company's policy is to deal only with creditworthy counterparties only.

Notes to standalone financial statements for the year ended 31st March, 2020

(b) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due.

(c) Market Risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest risk, currency risk and other price risk. Financial instruments affected by market risk include borrowings, deposits, Investments, trade and other receivables, trade and other payables and derivative financial instruments.

The sensitivity analysis in the following sections relate to the position as at 31st March, 2020 and 31st March, 2019.

28 Recent accounting pronouncements

Standards issued but not yet effective

The amendments to standards that are issued and new standards issued, but not yet effective, up to the date of issuance of the Company's financial statements are disclosed below. The Company intends to adopt these standards, if applicable, when they become effective. The Ministry of Corporate Affairs ("MCA") has issued certain amendments to Ind AS through (Indian Accounting Standards) Amendment Rules, 2019. These amendments maintain convergence with IFRS by incorporating amendments issued by International Accounting Standards Board (IASB) into Ind AS and has amended/issued the following standards:

1. Ind AS 116-Leases
2. Ind AS 12-Income Taxes
3. Ind AS 19-Employee Benefits

These amendments are effective for annual periods beginning on or after 1st April, 2019.

The Company is assessing the potential effect of the amendments on its financial statements. The Company will adopt these amendments, if applicable, from their applicability date.

29 In accordance with the requirements of Ind AS 24, Related Party Disclosures are as follows:

a) List of related parties

Relationship	Name of related party
Key Management Personnel (KMP)	Mr. Amit Agrawal (Managing Director) Mr. Raghav Agrawal (CFO) (14 th November, 2019 to till date) Mr. Dinesh Jain (CFO) (Upto 13 th November 2019) CS Prerna Kakkar (April, 2019 to till date)
Entities where significant influence is exercised by KMP having transactions with the Company	Deepshikha Exim Pvt. Ltd. Jindal Denim (India) Pvt. Ltd. Jindal Flocks Pvt. Ltd. Jindal Denims Inc. Jindal Fabric Inc. Gayatri Weavers Pvt. Ltd. Jindal Creations Pvt. Ltd. Jindal Spinning Inc. Tarachand & Sons T Pvt. Ltd Yash Weavers Ltd. Niharika Threads Pvt. Ltd. Saroj Weavers Pvt. Ltd. Balaji Weft Pvt. Ltd.

Notes to standalone financials statements for the year ended 31st March, 2020

b) Summary of Related Party Transactions

(Amount in ₹)

S. No	Particulars	Key management personnel		Entities where significant influence is exercised by KMP	
		2020	2019	2020	2019
	Transactions during the year				
i	Sale of goods and services				
	Deepshikha Exim Pvt. Ltd.			60,000	60,000
	Jindal Denim (India) Pvt. Ltd.			60,000	60,000
	Jindal Denims Inc.			359,000	315,000
	Jindal Fabric Inc.			300,000	315,000
	Gayatri Weavers Pvt. Ltd.			60,000	60,000
	Tarachand & Sons T Pvt. Ltd			60,000	60,000
	Jindal Creations Pvt. Ltd.			60,000	60,000
	Jindal Creations Inc.			60,000	30,000
	Jindal Spinning Inc.			148,500	75,000
	Yash Weavers Ltd.			120,000	135,000
	Niharika Threads Pvt. Ltd.			60,000	75,000
	Saroj Weavers Pvt. Ltd.			60,000	75,000
	Balaji Weft Pvt. Ltd.			60,000	75,000
ii	Salaries and other benefits	405,215	540,543		
iii	Rent Paid	10,000	-		

As per our report of even date

For, Saremal & Co.
Chartered Accountants

Pravin Lavana
(Partner)
Firm Registration No.: 109281W
Membership No. 037180

Place: Ahmedabad
Date : 26th June, 2020

For and on behalf of Board of Directors of
Kashyap Tele-Medicines Limited

Managing Director
(Mr. Amit Y Agrawal)
(DIN :00169061)

Company Secretary
(CS Prerna Kakkar)

Director
(Mrs. Amrita Khetan)
(DIN :02781781)

CFO/Director
(Mr. Raghav Agrawal)
(DIN :02264149)

SEBI CIRCULARS IN REGARDS TO PHYSICAL SHAREHOLDERS

MANDATORY UPDATION OF PAN, BANK ACCOUNT AND OTHER DETAILS:

Updating the necessary KYC details of registered and/or joint holders holding shares in physical form

We refer to the SEBI Circular No SEBI/HO/MIRSD/DOP1/CIR/P/2018/73 dated 20th April, 2018 & BSE Circular No. LIST/COMP/15/2018-19 dated 5th July 2018 by which they have directed all the listed companies to record the PAN, Bank account details of all their shareholders and advise them to dematerialise their physical securities. Accordingly your Company has initiated steps for registering the **PAN details** (including joint holders if any) and the **BANK ACCOUNT** details of all the registered shareholders.

We would also like to register other KYC details such as email id, mobile number, specimen signature and nomination. Your present status of each of these requirements is provided in the KYC form. We request you to kindly fill in the details in the KYC form and forward the same along with all the supporting documents based on requirements considering the below mentioned points. Single copy of supporting document is sufficient for updating multiple subjects.

A. For updating PAN of the registered and/or joint shareholders :

- Self- attested legible copy of PAN card (exempted for Shareholders from Sikkim)

B. For updating Bank Account details of the registered shareholder:

1. In cases wherein the original cancelled cheque leaf has the shareholder's name printed

- For address proof : Self- attested legible copy of Aadhaar/passport/utility bill (not older than 3 months)
- Original cancelled cheque leaf containing the Bank A/c No., Bank Name, type of account, IFSC Code, MICR Code and the name of the shareholder printed on the cheque leaf.

OR

2. In cases wherein the cancelled cheque leaf does NOT contain the shareholder's name printed on it

- For address proof : Self- attested legible copy of Aadhaar/passport/utility bill (not older than 3 months)
- Original cancelled cheque leaf containing the details, Bank A/c No., Bank Name, type of account, IFSC Code, MICR Code.
- Legible copy of the bank passbook / bank statement specifying the KYC details of the registered shareholder such as the name, address, bank account number etc. duly attested by the officer of the same bank with his signature, name, employee code, designation, bank seal & address stamp, phone no. and date of attestation.

C. For updating the Specimen signatures of the registered and/or joint shareholders :

- Affidavit duly notarised on non-judicial stamp paper of ₹ 100/- (format available on www.linkintime.co.in under Resources-Download-General-Change of Signature- Affidavit for change of signature).
- Banker's verification (format available on www.linkintime.co.in under Resources-Download-General-Change of Signature-format for signature verification)
- Original cancelled cheque containing the details, Bank A/c No., Bank Name, type of account, IFSC Code, MICR Code and the name of the shareholder printed on the cheque leaf.
- If the cancelled cheque leaf does not contain shareholder's name - legible copy of the bank passbook / bank statement specifying the KYC details of the registered shareholder such as the name, address, bank account number etc. duly attested by the officer of the same Bank with his signature, name, employee code, designation, bank seal & address stamp, phone no. and date of attestation.

D. For registering Email id of registered shareholder:

Email-id of the registered shareholder to be mentioned in the KYC form attached for all future communication in electronic mode (Go Green Initiative).

E. For registering Mobile No. of registered shareholder:

Mobile no. of registered shareholder for future direct communication

F. For registering Nominee by the registered shareholder (if any):

Nomination (Form SH-13) available on our RTA website i.e. www.linkintime.co.in under Resources-Downloads-General- Nomination.

We request you to kindly forward KYC form duly filled in, along with copies of supporting documents for all the "Required" remarks within 21 days from the date of this letter.

As per SEBI directive, enhanced due diligence procedure will be applicable if KYC requirements mentioned above are not fulfilled.

Inclined to serve you with the best of our services!!

KYC FORM

{Pursuant to SEBI Circular - dated 20th April, 2018}

To

Linkintime India Private Limited

C 101, 247 Park, L.B.S.Marg, Vikhroli (West), Mumbai - 400083.

Unit : **M/s. Kashyap Tele-Medicines Limited**

Regd. Office : 2nd Floor, Pushpawati Building No. 2,

Chandanwadi, Girgaon Road, Mumbai-400 002, MH

Corporate Office: UL/8, Upper Floor, "Suryarath", 1st Floor, Panchwati,

1st Lane, Ambavadi, Ahmedabad-380006, GJ

Dear Sir/Madam,

Date: // //

Folio No: _____

No of Shares: _____

We refer to the current KYC status as provided by you in the below table:

Barcode with co code+ folio

Name of the shareholder(s)	PAN (A)	Bank details (B)	Specimen Signature (C)	Email ID (D)	Mobile No. (E)	Nominee Details (F)

Based on the above data, we are forwarding herewith the required supporting documents by ticking in the appropriate checkbox below for all the fields where the status is shown as 'Required' in the above table).

A For registering PAN of the registered and/or joint shareholders (as applicable)

☐ Registered shareholder ☐ Joint holder ☐ Joint holder 2 ☐ Joint holder 3 (self-attested copy for all Shareholders attached)

B For registering Bank details of the registered shareholder

☐ Aadhar/Passport/utility bill ☐ Original cancelled cheque leaf ☐ Bank Passbook/Bank Statement

C For registering the Specimen Signature of registered and/or joint shareholders (as applicable)

☐ Affidavit ☐ Bank Verification ☐ Original cancelled cheque leaf ☐ Passbook/Bank Statement (for all Shareholders attached)

D For Updating the email id _____

E Mobile No

F For registering the nominee details by the registered shareholder

☐ Form SH-13 (Nomination registration form attached)

Note:-For residents of Sikkim instead of PAN provide Aadhar Card/Voters Card/Driving License/Passport or any other identity proof issued by Govt.

I /We hereby state that the above mentioned details are true and correct and we consent towards updating the particulars based on the self-attested copies of the documents enclosed with this letter by affixing my/our signature(s) to it

Sign: _____ Sign: _____ Sign: _____ Sign: _____
Registered holder Joint holder 1 Joint holder 2 Joint holder 3


Postal barcode

Mr/Ms/Mrs _____ (Registered holder)

(Address 1) _____

(Address 2) _____

(Address 3) _____



Kashyap Tele-Medicines Limited